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LIST OF ABBREVIATIONS 
 
µCT-scan Micro computed tomography scan 
ACE  Angiotensin converting enzyme 
ACK Ammonium-chloride-potassium 
ACPA  Antibodies to citrullinated protein antigens 
AS  Ankylosing spondylitis 
ASAS Assessment of spondyloarthritis 
ATP Adenosine triphosphate 
BASDAI Bath Ankylosing Spondylitis Disease Activity Index 
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BMDM Bone marrow-derived macrophage 
BSA Bovine serum albumin 
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CRP  C-reactive protein 
CTLA Cytotoxic T-lymphocyte-associated antigen 
DAMP Danger associated molecular pattern 
DAS28  28-joint disease activity score 
DAS28-CRP 28-joint disease activity score using C-reactive protein 
DAS28-ESR  28-joint disease activity score using erythrocyte sedimentation rate 
DMARD Disease-modifying antirheumatic drug 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EMA European Medicines Agency 
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FDA Food and Drug Administration 
GWAS  Genome-wide association studies 
H&E Hematoxylin and eosin 
HAQ-DI  Health assessment questionnaire-disability index 
HEK Human embryonic kidney 
HIF  Hypoxia-inducible factor 
HLA  Human leucocyte antigen 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HRE Hypoxia response element 
HRP Horseradish peroxidase 
IBD  Inflammatory bowel disease 
IFN  Interferon 
IgG Immunoglobulin gamma 
IKK  IkB kinase 
IL  Interleukin 
IMID  Immune-mediated inflammatory disease 
JAK  Janus kinase 
KO Knock-out 
LPS Lipopolysaccharide 
LysM Lysozyme M 
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 
MRI Magnetic resonance imaging 
mTSS  Modified total sharp score 
MyelKO Myeloid Knock-out 
NF-κB Nuclear factor-kappaB 
nr-axSpA  Non-radiographic axial spondyloarthritis 
NSAID  Nonsteroidal anti-inflammatory drug 
PBS Phosphate-buffered saline 
PHD  Prolyl hydroxylase domain 
PsA  Psoriatic arthritis 
P-STAT Phosphorylated signal transducer and activator of transcription 
pVHL Von Hippel-Lindau tumour suppressor protein 
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qPCR Quantitative polymerase chain reaction  
RA  Rheumatoid arthritis 
RCT  Randomized controlled trial 
REML Restricted maximum likelihood 
RF  Rheumatoid factor 
RNA Ribonucleic acid 
SC Subcutaneous 
SEC  Synovio-entheseal complex 
SHS  Sharp/van der Heijde score 
SLE  Systemic lupus erythematosus 
SNP Single-nucleotide polymorphism 
SpA  Spondyloarthritis 
STAT Signal transducer and activator of transcription 
TBK TANK-binding kinase 
TLR Toll-like receptor 
TNF  Tumor necrosis factor 
TNFAIP3 Tumor necrosis factor alpha-induced protein 3 
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Spondyloarthritis and rheumatoid arthritis: two prototypes of rheumatic diseases 
The field of rheumatology comprises several distinct diseases, of which spondyloarthritis 
(SpA) and rheumatoid arthritis (RA) are two well-known prototypes. Both SpA and RA are 
very prevalent; they each affect approximately  1% of the general population and can have a 
severe impact on the health-related quality  of life. [1,2] Although both diseases mainly 
affect the musculoskeletal system, there are also important differences between these two 
entities.  
 
Spondyloarthritis: from spine to joint 
The spondyloarthritis (SpA) concept consists of a heterogeneous group of rheumatic 
disorders, including ankylosing spondylitis (AS), non-radiographic axial SpA (nr-axSpA), 
psoriatic arthritis (PsA), arthropathy associated with inflammatory bowel disease (IBD) and 
reactive arthritis. At present, patients diagnosed with SpA are classified as having 
predominantly axial or predominantly peripheral SpA. Axial spondyloarthritis includes two 
subsets: ankylosing spondylitis (having significant sacro-iliitis on X-rays) or non-radiographic 
axial SpA. [3,4] [Fig 1] Hallmarks of SpA include articular manifestations such as sacro-iliitis, 
inflammatory back pain, asymmetric oligoarticular synovitis predominantly of the lower 
limbs, enthesitis and dactylitis as well as extra-articular features such as gut inflammation, 




Figure 1: Current concept of spondyloarthritis (SpA) 
 
Recently, substantial progress has been made in the treatment of SpA, especially in the field 
of biological therapies. However, it is important to keep in mind that the treatment of both 
axial and peripheral spondyloarthritis is addressed in a step-up manner.  
 
Exercise and physical therapy are cornerstones in the management of axial SpA. They are 
important to improve or maintain the mobility of the patient and can reduce their 
complaints. They should be implemented in the lives of both patients with early and more 
advanced axial SpA. Patient education and smoking cessation are also important 
components of axial SpA management. The first step in the pharmacological treatment of 
axial SpA are nonsteroidal anti-inflammatory drugs (NSAIDs). At least two courses of NSAIDs 
should be tried before moving on to second line therapy, except in the presence of NSAID 
toxicity. In this next phase sulfasalazine and/or local glucocorticoid injection should be 
considered in case of mainly peripheral manifestations. If this is not efficacious, if 
sulfasalazine is contra-indicated or if there is purely axial disease with a need for more 
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intense treatment a biological DMARD may be needed. In current practice, the first-choice 
biological DMARD is are tumor necrosis factor (TNF) blockers. If this is not efficacious a 





Figure 2: Algorithm based on the 2016 recommendations for the management of axial spondyloarthritis. 
Adapted from [6]  
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Education and exercise are also important in the management of psoriatic arthritis, the 
prototype of peripheral SpA. In the absence of prognostically unfavorable factors the first 
step in the treatment of PsA are NSAIDS, with or without association of local glucocorticoid 
injections. [7] If this treatment is inefficacious, in case of NSAID toxicity or in the presence of 
prognostically unfavorable factors, the next step is treatment with methotrexate. In case 
there is a contra-indication for the use of methotrexate, leflunomide, sulfasalazine or 
potentially cyclosporine A can be used as conventional synthetic DMARD. If this therapy is 
inefficacious or if toxicity occurs, treatment options depend on whether or not 
prognostically unfavorable factors are present. In case these factors are absent, treatment 
consists of a second conventional synthetic DMARD or a combination of two of these 
DMARDs. If this treatment is inefficacious or if there is DMARD toxicity, predominantly axial 
disease or severe enthesitis a biological DMARD may be needed. Usually TNF blocking agents 
are chosen as first-line biologicals. However, when contra-indications are present, an IL-
12/IL-23 inhibitor or an IL-17 inhibitor can be used. These biologic DMARDs can be combined 
with a conventional synthetic DMARD. Apremilast should be considered in patients with 
peripheral SpA and contra-indications for biologicals. In case of inefficacy or toxicity of the 
treatment a switch to another biologic DMARD or to a targeted synthetic DMARD can be 







Figure 3: Algorithm based on the 2015 recommendations for the management of psoriatic arthritis. Adapted 
from [7] 
 
Biologic DMARDS have changed the landscape of SpA treatment. The most frequently used 
biological DMARDs are the TNF blocking agents. This group consists of 2 subsets: monoclonal 
antibodies that target TNF-α (adalimumab, infliximab, golimumab and certolizumab pegol) 
and etanercept, which is a fusion protein that combines a soluble TNF-α receptor II and the 
immunoglobulin (Ig) G1 Fc region. [4,8] All TNF blocking agents demonstrated a good 
efficacy in both axial and peripheral SpA, including psoriatic arthritis. Moreover, all of them 
were effective in treating enthesitis. [reviewed in [4,9,10]] Although the TNF pathway is a 
key player in the pathogenesis of SpA, there are several other pathways involved that can 
also be targeted to treat spondyloarthritis. [table 1] 
 
IL12/IL23 signaling is inhibited by ustekinumab, a monoclonal antibody that targets the 
common p40 subunit of IL12 and IL23. Ustekinumab is approved for the treatment of 
psoriatic arthritis. Its efficacy has been demonstrated in a phase II randomized controlled 
trial (RCT) in 146 PsA patients using ACR20 response at week 12 as primary endpoint. [11] 
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Later, the efficacy of ustekinumab was confirmed in two large phase III RCT’s in respectively 
615 and 312 PsA patients using ACR20 response at week 24 as primary endpoint. [12,13] 
Long term follow-up showed that the efficacy of ustekinumab was maintained for at least 
two years. [14] Moreover, it was demonstrated that ustekinumab significantly reduced 
enthesitis in psoriatic arthritis patients. [12,13] The efficacy of ustekinumab in ankylosing 
spondylitis was investigated by means of a prospective open-label pilot study in 20 AS 
patients. At week 24, 65% of AS patients reached the ASAS40 response suggesting a good 
efficacy of ustekinumab in AS, although there was no significant effect on enthesitis in this 
study. [15] Phase III trials investigating the effect of ustekinumab in axial spondyloarthritis 
are currently ongoing. (clinicaltrials.gov) 
 
IL-17 signaling is another important therapeutic target in the treatment of spondyloarthritis. 
The best-known therapy targeting IL17 signaling is secukinumab, a monoclonal antibody 
directed against IL-17A. Secukinumab is approved for the treatment of both psoriatic 
arthritis and ankylosing spondylitis. In 2014, a phase II proof-of-concept trial in 42 PsA 
patients failed to meet the primary endpoint (ACR20 response at week 6), although the data 
suggested some clinical effect. [16] Later, two phase III RCTs in respectively 606 and 397 PsA 
patients showed a significant effect of secukinumab on the ACR20 response at week 24, 
demonstrating its efficacy in the treatment of PsA. [17,18] A significant effect of 
secukinumab on enthesitis in PsA was demonstrated in one of these trials. [17] A phase II 
RCT in 30 AS patients demonstrated efficacy of secukinumab on ASAS20 response at week 6. 
[19] The efficacy of secukinumab (dosed at 150mg) was confirmed in two phase III trials in 
respectively 371 and 219 AS patients using ASAS20 at week 16 as a primary endpoint. [20] A 
second monoclonal antibody targeted against IL-17A is ixekizumab. A phase III RCT in 417 
PsA patients demonstrated efficacy of ixekizumab in the treatment of psoriatic arthritis using 
ACR20 at week 24 as a primary endpoint. Moreover, it was demonstrated that ixekizumab 
has a significant effect on enthesitis. [21] Phase III clinical trials (further) investigating the 
effect of ixekizumab in psoriatic arthritis and axial spondyloarthritis are currently ongoing. 
(clinicaltrials.gov) A third therapy targeting IL-17 signaling is brodalumab. Brodalumab is a 
monoclonal antibody directed against the IL-17 receptor. A phase II randomized controlled 
trial in 168 PsA patients demonstrated the efficacy of brodalumab in PsA using ACR20 
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response at week 12 as a primary endpoint. [22] A Phase III RCT assessing the efficacy of 
brodalumab in axial SpA is currently ongoing and a phase III RCT further investigating the 
efficacy of brodalumab in PsA is completed, but not yet published. (clinicaltrials.gov)  
 
Therapies that inhibit IL-6 signaling include tocilizumab and sarilumab. Tocilizumab is a 
monoclonal antibody directed against both the soluble and membrane expressed IL-6 
receptors. A phase II RCT in 102 AS patients failed to demonstrate efficacy of tocilizumab in 
AS, causing further studies to be terminated. [23] Sarilumab is a monoclonal antibody 
targeted against the IL-6 receptor-α. A phase II RCT in 301 AS patients failed to demonstrate 
efficacy of sarilumab in the treatment of AS. No further studies assessing the efficacy of 
blocking IL-6 signaling in ankylosing spondylitis or psoriatic arthritis are currently ongoing. 
(clinicaltrials.gov) 
 
Another potential therapeutic option in SpA would be T-cell modulation. Abatacept for 
example is a fusion protein that combines the extracellular domain of human cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) and the Ig G1 Fc region. By binding to CD86 and 
CD80 it inhibits T cell signaling and activation. Interestingly, a phase II trial in 170 psoriatic 
arthritis patients showed a significantly higher ACR20 response rate at 24 weeks in patients 
that were treated with abatacept (10mg/kg) compared to placebo. There are no data on its 
effect on enthesis. [24] A phase III RCT further investigating the effect of abatacept in PsA is 
currently ongoing. (clinicaltrials.gov) However, in a prospective open-label pilot study in 15 
TNF blocking agent naïve AS patients and 15 AS patients with inadequate response to TNF 
blocking agents, abatacept failed to demonstrate efficacy.[25] Currently no further studies 
on the efficacy of abatacept in AS are currently being performed. (clinicaltrials.gov) Alefacept 
is a fusion protein combining the extracellular CD2-binding region of the human leucocyte 
function antigen-3 (LFA-3) and the IgG1 Fc region. Alefacept also acts as a T cell modulator. A 
phase II RCT in 185 PsA patients demonstrated that methotrexate in combination with 
alefacept resulted in a higher ACR20 response at week 24 compared to methotrexate 
combined with placebo. [26] There are no data on its effect on enthesitis and no studies 
were performed investigating the effect of alefacept in AS patients.  
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Inhibition of phosphodiesterase 4 (apremilast) is an approved therapy for psoriatic arthritis. 
The efficacy of Apremilast in psoriatic arthritis was demonstrated in a phase III RCT in 504 
PsA patients and in a phase II RCT in 204 PsA patients. [27–29] Moreover, apremilast is 
shown to reduce enthesitis in PsA patients. [27] The efficacy of apremilast in ankylosing 
spondylitis was investigated by means of a small phase II RCT in 38 AS patients with active 
disease on MRI. The primary end point in this study (mean change in BASDAI at week 12 
compared with baseline) was not met. [30] A phase III RCT to further investigate the efficacy 
of apremilast in AS is currently ongoing. (clinicaltrials.gov) 
 
An important inflammatory pathway in rheumatic disorders is the Janus kinase-Signal 
Transducer and Activator of Transcription (JAK-STAT) pathway. Tofacitinib is an oral JAK 
inhibitor, which mainly inhibits JAK1 and JAK3. [31,32] Two phase III RCTs were conducted in 
respectively 422 TNF blocking agents naïve PsA patients and in 394 PsA patients with an 
inadequate response to TNF blocking agents. Both RCTs demonstrated the efficacy of 
tofacitinib in PsA treatment using ACR20 response at 12 weeks and change in Health 
Assessment Questionnaire Disability Index (ΔHAQ-DI) at 12 weeks compared to baseline as 
primary endpoints.[33,34] A phase II RCT in 207 ankylosing spondylitis patients 
demonstrated a clinical effect of tofacitinib (dosed at 5 or 10mg BID). [35] Several other 
inhibitors of JAK-STAT signaling are currently being investigated in rheumatoid arthritis, but 
at this moment no clinical trials investigating these JAK-STAT inhibitors in the treatment of 
SpA are ongoing. (clinicaltrials.gov) More information on these JAK-STAT inhibitors will be 




Table 1: Novel therapeutic options for AS and PsA 
Compound Mode of Action PsA AS 
TNFα    
Adalimumab Inhibition of TNFα activity 
FDA  + 
EMA + 
FDA  + 
EMA + 
Infliximab Inhibition of TNFα activity 
FDA  + 
EMA + 
FDA  + 
EMA + 
Certolizumab pegol Inhibition of TNFα activity 
FDA  + 
EMA + 
FDA  + 
EMA + 
Golimumab Inhibition of TNFα activity 
FDA  + 
EMA + 
FDA  + 
EMA + 
Etanercept Inhibition of TNFα activity 
FDA  + 
EMA + 
FDA  + 
EMA + 
Phosphodiesterase 4    
Apremilast Inhibition of phosphodiesterase 4  
FDA  + 
EMA + 
 
IL-12/23    




IL-17    
Brodalumab Inhibition of IL-17 signaling   





Ixekizumab Inhibition of IL-17 signaling   
JAK    
Tofacitinib Inhibition of Janus kinases   
IL-6    
Tocilizumab Inhibition of IL-6 signaling   
Sarilumab Inhibition of IL-6 signaling   
T-cell activation    
Abatacept inhibition of T cell activation   
Alefacept Inhibition of T cell activation   
 
       Therapy is approved for this indication 
 
       Potentially effective or ongoing trials (clinicaltrials.gov) 
 
       Negative outcome  
 
No ongoing trials (clinicaltrials.gov) and no published randomized controlled trials 
 
 






Rheumatoid arthritis: a prototypical auto-immune rheumatic disorder 
Rheumatoid arthritis is the prototype of an auto-immune rheumatic disorder. Hallmarks of 
the disease are polyarticular symmetrical synovitis predominantly of the hand and feet, 
destruction of cartilage and bone, auto-immunity, biochemical inflammation and extra-
articular manifestations such as vasculitis. Patients can be classified as having a seropositive 
(detection of antibodies to citrullinated protein antigens (ACPA) or rheumatoid factor (RF) in 
the blood) or seronegative rheumatoid arthritis. Recently, an increasing amount of evidence 
suggests that these two subsets should actually be regarded as separate diseases and it is 
suggested that they have a different pathogenesis, prognosis and response to treatment. 
[36,37] 
 
The first-line treatment of rheumatoid arthritis consists of a conventional synthetic DMARD, 
preferably methotrexate. In case methotrexate is contra-indicated, the first step in the 
treatment of RA consists of leflunomide or sulfasalazine. Initial combination of these 
DMARDs with glucocorticoids should be considered, but given the side effects of chronic 
glucocorticoid use they should be tapered as soon as possible. [38] The recent CARERA trial 
demonstrates that methotrexate combined with moderate-dose corticosteroids used in a 
step-down manner is an effective and safe treatment option in the initial therapy of early 
rheumatoid arthritis, if a treat-to-target approach is used. [39] Intra-articular administration 
of glucocorticoids can be considered to treat local inflammation. [38] Patient education, 
dynamic exercise, occupational therapy, smoking cessation, weight control, dental care, 
vaccination management and treatment of co-morbidities are important components of the 
management of RA. [40] The target that needs to be reached in rheumatoid arthritis 
treatment is remission as defined by the ACR-EULAR. If it is likely that remission is not 
achievable, the aim of the treatment is to at least achieve low disease activity. The 
treatment target should be reached after a treatment period of maximum 6 months. 
However, if there is insufficient improvement after 3 months, the treatment should be 
adapted without waiting for the 6-month result. In case long-term remission is obtained, a 
dose reduction of the medication should be considered. If the treatment target is not 
reached or if intolerance/toxicity of the treatment occurs in this first step, the next step in 
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the treatment of rheumatoid arthritis depends on the presence of unfavorable prognostic 
factors. In the absence of unfavorable prognostic factors, a switch to another conventional 
synthetic DMARD is recommended. Combination with low dose glucocorticoids is preferred. 
If the treatment target is not reached in this treatment step, if toxicity occurs or if 
unfavorable prognostic factors are present, the addition of a biologic DMARD or a JAK-
inhibitor is recommended. In case the efficacy is still insufficient or in case 





Figure 4: Algorithm based on the 2016 European League Against Rheumatism recommendations on 
rheumatoid arthritis management. Adapted from [38] 
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During the last years, several new biologic and synthetic treatment options for rheumatoid 
arthritis were being approved or investigated. [Table 2]  
 
All five TNF blocking agents that are used in the treatment of SpA are also approved for the 
treatment of rheumatoid arthritis. Adalimumab, infliximab, certolizumab pegol, golimumab 
and etanercept have all been demonstrated to be efficacious in the treatment of RA. 
Moreover, it was shown that although they have different pharmacokinetic as well as 
pharmacodynamic properties, they have a similar efficacy in the treatment of RA. [reviewed 
in [41]] 
 
Several JAK inhibitors have been developed during the past years and are being investigated 
in rheumatoid arthritis. Tofacitinib is approved for the treatment of RA. Multiple studies 
have demonstrated the efficacy of tofacitinib in the treatment of rheumatoid arthritis. 
[reviewed in [42]] A second JAK inhibitor investigated in the treatment of RA is baricitinib. 
Baricitinib mainly inhibits JAK1 and JAK2. It is approved for the treatment of rheumatoid 
arthritis by EMA, but not by FDA yet. Its efficacy has been demonstrated in several clinical 
trials. [reviewed in [43]] ABT-494 is a selective JAK1 inhibitor. ABT-494 demonstrated 
efficacy in the treatment of RA in a phase II trial on 276 patients using the ACR20 response at 
week 12 as a primary endpoint. [44] Moreover the efficacy of ABT-494 on the ACR20 
response at week 12 was confirmed for a dose of 6, 12 and 24mg a day in a phase II trial in 
300 RA patients. [45] Several phase III trials further investigating the effect of ABT-494 in 
rheumatoid arthritis are currently ongoing. (clinicaltrials.gov) Filgotinib is another selective 
JAK1 inhibitor. Filgotinib (dosed 100mg once a day, 100mg twice a day and 200mg once a 
day) demonstrated efficacy in a phase II trial in 594 RA patients using ACR20 response at 
week 12 as a primary endpoint. [46]The efficacy of filgotinib on the ACR20 response at week 
12 was confirmed in a phase II trial in 283 RA patients. [47] Several phase III trials further 
investigating the effect of filgotinib in rheumatoid arthritis are currently ongoing. 
(clinicaltrials.gov) Peficitinib is a JAK inhibitor with a moderate selectivity for JAK3. Peficitinib 
(dosed 50, 100 or 150 mg per day) demonstrated efficacy in a phase II trial in 281 RA 
patients using ACR20 at week 12 as a primary endpoint.[48] However, in a second phase II 
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trial in 378 RA patients peficitinib only achieved the primary endpoint (ACR20 at week 12) 
when using a dose of 50mg a day. The primary endpoint was not achieved for the doses 25, 
100 or 150mg a day.[49] A third phase II trial in 289 RA patients demonstrated significant 
efficacy of peficitinib on the ACR20 response at week 12 if dosed 100 or 150mg a day. 
Statistical significance was not obtained for the 25 and 50mg a day doses.[50] Several phase 
III trials further investigating the efficacy of peficitinib in rheumatoid arthritis are currently 
ongoing. (clinicaltriams.gov) 
 
Another therapeutic target in the treatment of rheumatoid arthritis is IL-6 signaling. 
Tocilizumab, a monoclonal antibody directed against the soluble and membrane expressed 
IL-6 receptor, is currently the only approved therapy targeting IL-6 signaling in RA. The 
efficacy of tocilizumab has been demonstrated in several clinical trials. [as reviewed in [51]] 
Sarilumab, a monoclonal antibody targeted against IL-6 receptor-α, has demonstrated its 
efficacy using the ACR20 response at week 12 as a primary endpoint in a phase II trial in 306 
RA patients in following dosing regimens: 150mg once a week, 150mg every two weeks or 
200mg every two weeks.[52] The efficacy of sarilumab was confirmed in a phase III trial in 
1369 RA patients where it met all three co-primary endpoints (ACR20 response at week 24, 
change from baseline in the HAQ-DI at week 16 and change from baseline in the modified 
Sharp/van der Heijde score (SHS) of radiographic damage at week 52). [53] Another phase III trial in 
369 RA patients demonstrated that sarilumab monotherapy is more efficacious than adalimumab 
monotherapy in the treatment of RA using change from baseline in the 28-joint disease activity score 
using erythrocyte sedimentation rate (DAS28-ESR) at week 24 as a primary endpoint. [54] The 
efficacy of sarilumab was confirmed in a third phase III trial in 546 RA patients using ACR20 response 
at week 24 and change from baseline in the HAQ-DI at week 12 as primary endpoints. [55] Sirukumab 
is a monoclonal antibody targeted against IL-6. The efficacy of sirukumab (dosed 100mg every 2 
weeks) has been demonstrated in a phase II trial in 151 RA patients using ACR50 response at week 12 
as a primary endpoint. However, the primary endpoint was not met for the following dosing 
regimens: 100, 50 or 25mg every 4 weeks. [56] The efficacy of sirukumab was also demonstrated in a 
phase III trial in 878 RA patients. The primary endpoint (ACR20 at week 16) was met with both the 
50mg every 4 weeks and 100mg every 2 weeks dosing regimen. [57] In a second phase III trial in 559 
RA patients it was demonstrated that sirukumab had a better effect on the change from baseline for 
DAS28-ESR at week 24 compared to adalimumab, while the effect on the ACR50 response at week 24 
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was comparable. [58] Moreover, in a third phase III trial in 1374 RA patients it was shown that 
sirukumab has a significant effect on the radiographic progression in rheumatoid arthritis. [59] The 
second monoclonal antibody targeting IL-6 is olokizumab. Olokizumab has demonstrated its efficacy 
in two phase II trials in respectively 221 and 119 RA patients using change from baseline in DAS28-C-
reactive protein (CRP) at week 12. [60,61] Moreover, it has been demonstrated that the efficacy of 
olokizumab was maintained for at least 48 weeks. [62] Several phase III trials investigating the 
efficacy of olokizumab in rheumatoid arthritis are currently ongoing. (clinicaltrials.gov) Clazakizumab 
is the third monoclonal antibody targeted against IL-6 that is currently being investigated in 
rheumatoid arthritis. Its efficacy has been demonstrated in a phase II trial in 418 RA patients using 
ACR20 at week 12 as a primary endpoint. [63] Currently no studies further investigating the effect of 
clazakizumab in the treatment of RA are ongoing. (clinicaltrials.gov) 
 
Targeting IL-1 signaling is a therapeutic option in rheumatoid arthritis. Anakinra, a recombinant IL-1 
receptor antagonist, is approved for the treatment of RA. It was demonstrated to be efficacious in 
rheumatoid arthritis, but its effect was rather moderate. [as reviewed in [64,65]] Canakinumab on 
the other hand is a monoclonal antibody targeting IL-1β. The efficacy of canakinumab (dosed: 150mg 
SC every 4 weeks) has been demonstrated in a phase II trial in 274 RA patients using ACR50 response 
at week 12 based on a 28-joint count as a primary endpoint. However, the primary endpoint was not 
met for following dosing regimens: 300mg SC every 2 weeks or 600mg IV followed by 300mg SC 
every 2 weeks. [66] At this moment no clinical trials further investigating the efficacy of canakinumab 
in rheumatoid arthritis are ongoing. (clinicaltrials.gov) 
 
B-cell depletion is a mode of action that can be used in the treatment of rheumatoid arthritis. 
Rituximab is a monoclonal antibody directed against the CD20 protein found on B cells and it 
induces B cell depletion. Rituximab is approved for the treatment of RA and its efficacy has 
been demonstrated in several clinical trials. [as reviewed in [67]] Ocrelizumab and 
ofatumumab are also monoclonal antibodies directed against the CD20 protein found on B 
cells that result in B cell depletion. Ocrelizumab and ofatumumab have demonstrated their 
efficacy in several clinical trials. Ofatumumab is associated with infusion-related adverse 
events, but no association between ofatumumab and serious infections was found. 
However, ocrelizumab was suspected to be associated with serious infections [as reviewed 
in [68]], which led to the premature termination of multiple clinical trials. (clinicaltrials.gov) 
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Three clinical trials investigating the safety and efficacy of ofatumumab in RA were 
terminated due to the sponsors decision to refocus development on subcutaneous 
administration. (clinicaltrials.gov) It was concluded that repeated open-label ofatumumab 
treatment in these trials was generally well tolerated and that serious infections were 
uncommon.[69] At the moment no clinical trials further investigating the efficacy of 
ofatumumab in rheumatoid arthritis are ongoing. (clinicaltrials.gov)  
 
T cell modulation is also a therapeutic option in rheumatoid arthritis. Abatacept is a fusion 
protein combining the extracellular domain of human CTLA-4 and the IgG1 Fc region. This 
protein binds to CD86 and CD80 and inhibits T cell signaling and activation. The efficacy of 
abatacept has been demonstrated in several clinical trials. [reviewed in [70]]  
 
Targeting IL-17 signaling has proven efficacious for the treatment of SpA. Several compounds 
targeting IL-17 signaling have been investigated in rheumatoid arthritis. Secukinumab failed 
to reach the primary endpoint (ACR20 response at respectively week 12 and week 16) in two 
phase II trials in respectively 221 and 237 RA patients. [71,72] Interestingly, another phase II 
trial in 100 RA patients did demonstrate a significant effect of secukinumab on the ACR20 
response after 12 weeks. [73] Moreover, secukinumab (dosed 150mg every 4 weeks) was 
demonstrated to have a significant effect on the ACR20 response at week 24 in a phase III 
trial in 551 RA patients, while the primary endpoint was not met with secukinumab dosed 
75mg every 4 weeks. [74] A second therapy blocking IL-17 signaling is ixekizumab. A phase II 
study in 448 patients demonstrated efficacy of ixekizumab on the ACR20 response at week 
12. [75] An open-label extension of this trial showed that the clinical benefit of ixekizumab 
was maintained or even improved during long term therapy. [76] The third therapy targeting 
IL-17 signaling that is investigated in rheumatoid arthritis is brodalumab. A phase II RCT in 
252 RA patients failed to demonstrate efficacy of brodalumab in the treatment of RA. [77] All 
these observations clearly demonstrate that inhibition of IL-17 signaling in the treatment of 
RA does not have the good efficacy seen in the treatment of SpA. At this moment, no further 
studies investigating the effect of blocking IL-17 signaling in rheumatoid arthritis are 
ongoing. (clinicaltrials.gov)  
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The oral phosphodiesterase 4 inhibitor apremilast did not show efficacy in the treatment of 
RA in a phase II RCT in 237 RA patients. [78] No further clinical trials investigating apremilast 
in rheumatoid arthritis are currently ongoing. (clinicaltrials.gov) 
 
Ustekinumab failed to demonstrate efficacy in a phase II trial in 274 RA patients using ACR20 
response at week 28 as a primary endpoint. [79] No further clinical trials investigating 
ustekinumab in rheumatoid arthritis are currently ongoing. (clinicaltrials.gov) 
 
Table 2: Novel therapeutic options for RA 
Compound Mode of Action RA 
TNFα   
Adalimumab Inhibition of TNFα activity 
FDA  + 
EMA + 
Infliximab Inhibition of TNFα activity 
FDA  + 
EMA + 
Certolizumab pegol Inhibition of TNFα activity 
FDA  + 
EMA + 
Golimumab Inhibition of TNFα activity 
FDA  + 
EMA + 
Etanercept Inhibition of TNFα activity 
FDA  + 
EMA + 
Phosphodiesterase 4   
Apremilast Inhibition of phosphodiesterase 4   
IL-12/23   
Ustekinumab Inhibition of IL-12/IL-23 signaling  
IL-17   
Brodalumab Inhibition of IL-17 signaling  
Secukinumab Inhibition of IL-17 signaling  
Ixekizumab Inhibition of IL-17 signaling  
JAK   
Tofacitinib Inhibition of JAK-STAT signaling 
FDA + 
EMA + 
Baricitinib Inhibition of JAK-STAT signaling EMA + 
ABT-494, Inhibition of JAK-STAT signaling  
Filgotinib Inhibition of JAK-STAT signaling  
Peficitinib Inhibition of JAK-STAT signaling  
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IL-6   
Tocilizumab Inhibition of IL-6 signaling 
FDA  + 
EMA + 
Sarilumab Inhibition of IL-6 signaling  
Sirukumab Inhibition of IL-6 signaling  
Olokizumab Inhibition of IL-6 signaling  
Clazakizumab Inhibition of IL-6 signaling  
IL-1   
Anakinra Inhibition of IL-1 signaling 
FDA  + 
EMA + 
Canakinumab Inhibition of IL-1 signaling  
B-cell depletion   
Rituximab Depletion of B cells 
FDA  + 
EMA + 
Ocrelizumab Depletion of B cells  
Ofatumumab Depletion of B cells  
T-cell activation   
Abatacept Inhibition of T cell activation 
FDA  + 
EMA + 
 
          Therapy is approved for this indication 
  
         Potentially effective or ongoing trials (clinicaltrials.gov) 
 
          Negative outcome  
 
       No ongoing trials (clinicaltrials.gov) and no published randomized controlled trials 
 
 





Pathophysiology of RA and SpA: a complex interplay between genetics and environment 
It is clear that the efficacy of several modes of action drugs differs in the treatment of RA 
versus SpA. This indicates that, although some pathways are involved in the pathogenesis of 
both diseases, others are only important in one of both diseases. Clearly, the TNF pathway is 
a key player in both spondyloarthritis and rheumatoid arthritis. [reviewed in [4,80–82]] TNF 
blocking agents were the first biologics that were used in the treatment of SpA and RA and 
they are still key components in the management of these diseases. While an important role 
for IL-17 signaling is suggested in both the pathogenesis of SpA and RA, blocking IL-17 
signaling is clearly more efficacious in the treatment of SpA than in RA. [4,82] This suggests a 
different role for the IL-17 signaling in the pathogenesis of both diseases. One of the most 
striking differences in the pathogenesis of SpA and RA is the role of IL-6 signaling. While 
blocking IL-6 signaling is a very efficacious and approved therapy in rheumatoid arthritis, it 
failed to demonstrate efficacy in ankylosing spondylitis. [10,19,82] This may be linked to the 
fact that IL-6 has an important role in the epithelial homeostasis. Interestingly, disturbance 
of the epithelial barrier is a major component of the pathogenesis of both ankylosing 
spondylitis and psoriatic arthritis, since it leads to microbial challenge and adaptive immune 
response induction. However, the pathogenesis of rheumatoid arthritis appears to be not 
based on the disruption of epithelial barrier, but rather auto-antibody production (a 
hallmark of disturbed adaptive immunity) plays an important role in its pathogenesis. This 
could explain why IL-6, which is involved in antibody production is an effective therapy for 
RA while this seems not the case for AS and PsA.  [83,84] However, this remains to be 
proven. All these observations indicate that the inflammation in RA and SpA depends upon 
cytokine networks that share certain, but not all pathways. Different inflammatory 
(rheumatic) disorders are defined by a cytokine hierarchy and can be classified based on 
their molecular pathophysiology. [84]  
 
Much remains unknown about the pathogenesis of rheumatoid arthritis and 
spondyloarthritis, but it is clear that both genetic and environmental factors are involved. 
The link between SpA and human leucocyte antigen (HLA)-B27 has been recognized for years 
[85], but it was recently shown by means of genome-wide association studies (GWAS) that 
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other genetic factors can also be involved in the pathogenesis of SpA. [80] For example, 
GWAS studies demonstrated genetic associations between AS and both the TNF and the 
interleukin (IL)-23/IL-17/IL-22 signaling pathway [80] In the pathogenesis of RA, strong 
association between seropositive RA and certain HLA-DRB1 alleles has been established a 
long time ago. [86] Moreover, GWAS studies showed that several SNP’s in genes involved in 
the immune system, can be involved in the pathogenesis of seropositive RA, including genes 
involved in the TNF/NF-κB pathway or in the regulation of the T-cell function. [37,87] 
Genetic factors are also important in the pathogenesis of seronegative RA and include for 
example HLA-DRB1*03 allele, lectin binding proteins and interferon regulatory factors. [37] 
 
The genetic component of the pathogenesis of SpA and RA is complex and it is clear that it 
should be seen in association with environmental factors. Mechanical stress is an interesting 
example of how the interplay between genetics and environment is of the utmost 
importance in the pathogenesis of SpA. TNFΔARE mice are genetically altered to have a 
chronic deregulated TNF expression. This leads to the development of a phenotype 
resembling SpA with features such as enthesitis, synovitis and ileitis. It was shown in the 
TNFΔARE mouse model that reducing mechanical stress on the entheses of the Achilles 
tendons by unloading the hind paws, significantly reduced the amount of entheseal 
inflammation, indicating the importance of mechanical stress in the pathogenesis of SpA. 
[88] Another important environmental factor in the pathogenesis of SpA is the gut 
microbiome. HLA-B27 transgenic rats are known to develop inflammation of the intestine, 
joints, skin and male genitals and are frequently used as an animal model for SpA. 
Interestingly, if these animals are kept in a germfree environment they do not develop 
inflammatory lesions in the intestine or joints, demonstrating the importance of gut 
microbiome in the pathogenesis of ileitis and joint inflammation in SpA. Moreover, since the 
inflammation of the skin and male genitals was unaffected in germfree conditions, these 
data suggest that different SpA features have a distinct pathogenesis. [89] Environmental 
factors are also involved in the pathogenesis of RA. A clear association was demonstrated 
between smoking and both the incidence and severity of seropositive rheumatoid arthritis. 
[90,91] Furthermore, associations are demonstrated between RA and periodontal pathology 
and it is suggested that microbiota are involved in the pathogenesis of RA. [37,92,93] 
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This thesis focusses on myeloid cells since these cells play a crucial role in the pathogenesis 
of both rheumatoid arthritis and spondyloarthritis. The synovium in rheumatoid arthritis is 
known to contain a large amount of myeloid cells and these cells are considered central 
effectors of synovitis. Myeloid cells play a major role in the production of cytokines, matrix-
degrading enzymes and reactive oxygen intermediates that are induced in the synovium 
during inflammation. Moreover, myeloid cells are known to mediate the activation and 
differentiation of T-cells, influencing the adaptive response in the pathogenesis of 
rheumatoid arthritis. [37] Myeloid cells also play an important role in the pathogenesis of 
enthesitis. As discussed in more detail later in the introduction, biomechanical stress is 
known to result in an inflammatory status in the entheses, reflected by increased 
vascularization and infiltration of macrophages. These macrophages will release cytokines , 
eventually leading to  articular inflammation. [94] Taken together, myeloid cells clearly 
function as key players in the pathogenesis of both rheumatoid arthritis and enthesitis, 
making them very interesting cells to focus on.  
 
Currently, a broad spectrum of animal models exists to study rheumatoid arthritis and 






















































































































































































































































































































































































































































































































































































































































































Overview of rheumatoid arthritis animal models 
  Induction Onset and evolution Inflammation characteristics 
Collagen-induced 
arthritis (CIA) 
• Induced by i.d. immunization 
with type II collagen (CII) 
emulsified in CFA 
• Onset at day 21–28 
• Self-resolving (around 
60 days in mice) 
• Synovium infiltration (T 
cells, B cells, macrophages 
and neutrophils) leading to 
pannus formation, 
hyperplastic membrane of 
synoviocytes, bone and 
cartilage destruction 
• T cell and B cell-specific 




• Administration of a cocktail 
of arthritogenic monoclonal 
antibodies directed against CII 
in mice, followed by a LPS 
boost at day 3.  
• 3–4 days after the 
initial disease induction 
step, the mice start 
developing 
inflammation. The 
incidence is 90–100%, 
and symptoms persist 
up to several weeks 
after the induction. 
• Macrophage and 
polymorphonuclear 
inflammatory cell infiltrate 





• i.p. immunization with 
proteoglycan (PG) isolated 
from cartilage (usually human) 
emulsified in CFA or 
dimethyldioctadecylammonium 
bromide (DDA)  
• Onset at days 21–28 • Development of 
polyarthritis, presence of 
rheumatoid factor, deposition 
of immune complexes in the 
joint, persistent joint 
inflammation 
• Development of ankylosing 
spondylitis 
• T cell and B cell-specific 




• A single intra-articular 
injection with SCW fragments 
in one knee joint leads to an 
acute arthritis. Flares can be 
obtained by subsequent 
intravenous injection of SCW 
fragments. 
• Rapid onset (1 day) • Multiple intra-articular 
injections of SCW fragments 
turn the acute inflammation 
into a chronic destructive 
arthritis 
• Joint, inflammation, 
proteoglycan depletion, and 
chondrocyte death 
K/BxN mice • Transgenic expression of a 
TCR specific for a peptide from 
bovine pancreatic 
ribonuclease.  
• Spontaneous arthritis 
development after breeding 
onto the NOD background 
• Purified IgGs or serum from 
arthritic K/BxN mice induce a 
transient arthritis in various 
mouse strains such as BALB/c, 
C57BL/6, and DBA/1 
• Onset 4 weeks after 
birth, 100% penetrance 
• T cell and B cell 
autoreactivity against the 
autoantigen glucose-6-
phosphate isomerase (G6PI), 
resulting in the production of 
pathogenic G6PI-specific 
autoantibodies. 
• Infiltration, pannus, 
synovitis, cartilage and bone 
destruction  




SKG mice • Spontaneous inflammatory 
arthritis attributed to a 
mutation in ZAP-70 
• No arthritis in a pathogen 
free environment 
• Transfer of T cells from 
arthritic SKG mice produces 
similar arthritis in T cell-
deficient athymic BALB/c nude 
mice, whereas transfer of the 
sera from the same SKG mice 
does not 
• Joint swelling 
macroscopically evident 
at about 2 months of 
age 
• Severe synovitis with 
massive subsynovial 
infiltration of neutrophils, 
lymphocytes, macrophages, 
and plasma cells, proliferation 
of synoviocytes, cartilage and 
bone erosion 
• T cell-mediated and also 
depends on innate immune 
stimuli 
• Rheumatoid factor, 
autoantibodies specific for CII 
TNF-α transgenic 
mouse 
• Human (h) TNF-α transgene 
in which the ARE-containing 3′-
UTR is replaced with the 3′-UTR 
from the β-globin gene leading 
to increased stability of TNF-α 
mRNA and subsequent hTNF-α 
expression 
• Onset at 4–6weeks 
after birth, 100% 
penetrance 
• Chronic progressive erosive 
polyarthritis on all joints 
• Synovial hyperplasia, as 
polymorphonuclear and 
lymphocytic infiltration in the 
synovial space, pannus 
formation, cartilage and bone 
destruction 




• Immunization with 
methylated bovine serum 
albumin (mBSA) in complete 
Freund’s adjuvant followed by 
knee joint injection after 
21days with mBSA in saline 
• Onset 1 day after knee 
joint injection with 
mBSA 
• mBSA-specific CD4+ T cells 
provide the initial 
inflammatory stimulus, 
leading to recruitment of 
neutrophils and macrophages 
• Synovial hyperplasia of the 
synovial lining layer, 
infiltration of the synovial 
sublining by leukocytes, loss 
of proteoglycans from the 
articular cartilage only in 
mBSA-injected joint 
 




Enthesitis is a hallmark of spondyloarthritis: importance of the synovio-entheseal complex 
Enthesitis is known to be an important feature of SpA, especially enthesitis of the Achilles 
tendon and the fascia plantaris. [figure 5] Moreover, in SpA patients enthesitis and synovitis 
appear to be closely linked. The enthesis based model of SpA pathogenesis even 
hypothesizes that synovitis in SpA results from inflammatory signals originating in the 
enthesis. Because the synovium and the enthesis are located in close proximity to one 
another and because there is a functional association between the two, they can be 
regarded as a synovio-entheseal complex (SEC). A good example of such a SEC is located at 
the Achilles tendon insertion, where it includes the enthesis itself, the retrocalcaneal bursa, 
fibrocartilage and the tip of the Kager’s fat pat, which is covered with synovium. [figure 6] 
While entheses are prone to microdamage due to the mechanical stress that is put upon it, 
the entheseal tissue itself has a low susceptibility to inflammation because of the 
avascularity of the enthesis in normal circumstances and the lack of macrophages in this 
tissue. Synovia on the other hand are well vascularized and comprise resident macrophages, 
which makes the synovial tissue very susceptible to inflammation. If microdamage arises in 
the enthesis, this can lead to inflammation of the synovium or even to inflammation of the 
entire SEC. [98–100]  
 
 




Figure 6: The synovio-entheseal complex: adapted from [98] 
This figure represents the concept of a synovio-entheseal complex by using the Achilles tendon as an example. 
The synovial membrane is located in close anatomical proximity to the enthesis. It lines a large part of the 
retrocalcaneal bursa. The other part of the bursa is lined by sesamoid fibrocartilage (located in the deep part of 
the tendon) and periosteal fibrocartilage (located at the superior tuberosity of the calcaneus). Macrophages 
are abundantly present in the synovium and combined with good vascularization makes it prone to 
inflammation.  
 
Although enthesitis is an important hallmark of spondyloarthritis, the molecular mechanisms 
underlying the pathogenesis of enthesitis remain largely unknown. Recently, it was 
demonstrated that IL-23 is involved in the pathogenesis of enthesitis and that IL-23 exerts its 
function via IL-23 receptors on entheseal resident T cells. This will induce the expression of 
several cytokines such as IL-22, IL-17 and I-L6. IL-22 will activate STAT3 and this will lead to 
bone remodeling. [101] However, another study demonstrated that enthesitis in TNFΔARE 
mice was T cell independent and that stromal cells are likely to play a role in the 
pathogenesis of enthesitis. [88] These observations indicate that both T cell dependent and 
independent factors can be involved in the pathogenesis of enthesitis and that 




Spondyloarthritis versus rheumatoid arthritis: auto-immunity versus auto-inflammation 
Arthritis is a feature of both RA and SpA, but there are clear differences between the two 
forms of arthritis. [figure 7] As mentioned before, it is hypothesized that arthritis in SpA 
actually originates from the enthesis, while in rheumatoid arthritis fibroblast-like 
synoviocytes play a central role in the pathogenesis of arthritis. [98,102] 
 
The synovium consists of two layers: the lining layer and the sublining layer. The former 
consists of fibroblast-like synoviocytes and macrophages, while the latter contains less cells 
and mainly consists of loose connective tissue, fat and blood vessels. [98,102] In rheumatoid 
arthritis hyperplasia of both the lining and the sublining layer occur. The synovium will form 
a pannus that invades the adjacent cartilage and bone, leading to cartilage destruction and 
bone erosions. [102] It was demonstrated that in SpA the lining layer of the synovium is not 
as hyperplastic compared to the synovial lining layer in RA and some studies even showed 
that the vascularity of the synovium differs between RA and SpA. [98,103–105]  
 
 
Figure 7: Differences between arthritis in RA and SpA (arthritis of the knee) [106] 
36 
 
While rheumatoid arthritis is considered to be an auto-immune disorder, spondyloarthritis is 
positioned more towards the auto-inflammatory side of the immunological disease 
continuum. In both auto-immune and auto-inflammatory disorders there is self-directed 
inflammation, but the cause differs between the two. In auto-immunity dysregulation of the 
adaptive immune system leads to a break in tolerance and immune reactivity towards self-
antigens Auto-antibodies may be present years before clinical symptoms occur. In auto-
inflammation on the other hand, the primary problem are local factors at sites prone to 
disease. Here, activation of the innate immune system leads to tissue inflammation and 
damage. However, it is important to keep in mind that most diseases have features of both 
auto-immunity and auto-inflammation and that these concepts form a continuum rather 
than a rigid classification system. This concept can explain the difference in arthritis in RA 
and in SpA; while arthritis in rheumatoid arthritis begins as an auto-immune synovitis, the 
origin of arthritis in spondyloarthritis is pinpointed to local factors in tissues prone to the 
disease, like entheses. [107] 
 
The interplay between hypoxia and inflammation 
All cells fundamentally require oxygen to function. However, joints are known for their 
physiologically low oxygen level and interestingly, inflammation even reduces the amount of 
oxygen that is available in the synovial fluid. [108] Longstanding research has been 
performed concerning the link between inflammation and hypoxia. Already in the early 70’s 
synovial fluids of patients with diseased knee joints, most of which were diagnosed with 
rheumatoid arthritis, were analyzed for partial oxygen pressure and it was demonstrated 
that diseased joints had a lower partial oxygen tension. [109] Moreover, the oxygen tension 
in synovial fluid from patients with RA was considerably lower than in patients with 
osteoarthritis or traumatic effusion. [109,110] It was suggested that this was caused by an 
increased metabolic demand by the inflamed tissues that could not be met despite the 
increased blood flow in the joints. [109] Another hypothesis is that vasculitis in the joints 
leads to a reduced oxygen supply, while due to hyperplasia the amount of tissue increases 
and the metabolic demands are also higher in an inflamed joint. [110] A third hypothesis 
suggests that hypoxia is caused by an increased angiotensin converting enzyme (ACE) 
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expression in the synovium of diseased joints. ACE will catalyze angiotensin II formation, 
which is a potent vasoconstrictor. [111] Hypoxia is able to induce angiogenesis, inflammation 
and cartilage destruction, so it is hypothesized to have a role as pathologic factor in 
rheumatoid arthritis. [112] Interestingly, it was demonstrated that in a collagen induced 
arthritis model hypoxia is already present in the joints before arthritis occurred, suggesting 
that the role of HIF is not necessarily limited to maintaining the inflammation, but HIF can 
also be involved in the induction of arthritis. [113] These observations also suggest that the 
synovial hyperplasia and increased metabolic demands only contribute to maintaining the 
hypoxic status in arthritis, but that they are not involved in the induction of hypoxia. [112] 
 
Hypoxia-inducible factor (HIF) is known to be an important regulator of the cellular response 
to hypoxia. [114–116] It functions as a transcription factor by heterodimerization of 2 
proteins: HIF-α and HIF-β. [114,117] The HIF-α subunit is regulated by the oxygen status in 
the cell, the HIF-β subunit on the other hand is constitutively expressed. [112] At present, 
three HIF-α subunits are identified: HIF-1α, HIF-2α and HIF-3α. [114,117,118] The role of 
hypoxia and HIF in the pathogenesis of arthritis is not fully understood. Chronic intermittent 
hypobaric hypoxia (CIHH) is shown to have a protective effect on arthritis in a collagen-
induced arthritis (CIA) model in rats by increasing apoptosis in synoviocytes and T-
lymphocytes. [119,120] However, both HIF-1α and HIF-2α are considered to be pathogenic 
factors in the pathogenesis of RA. [reviewed in [112]] Moreover, it was demonstrated that 
hypoxia is able to activate NF-κB signaling and induce inflammation. [112,121–124]  
 
The main regulators of HIF-α degradation are the intracellular oxygen sensors known as HIF 
prolyl hydroxylase domain (PHD) proteins. There are three known isotypes: PHD1, PHD2 and 
PHD3. In normoxic circumstances the HIF1α concentration in the cell is low because the 
prolyl hydroxylases will hydroxylate HIF1α so it can be degraded in the proteasomes. 
However, in hypoxic circumstances the ability of the HIF prolyl hydroxylases to hydroxylate 
HIF-α will be inhibited since these enzymes need oxygen as a substrate for the hydroxylation 
to take place. This leads to an increased HIF1α concentration in the cell during hypoxic 
circumstances. HIF-α will translocate to the nucleus, heterodimerize with HIF-β and bind to 
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hypoxia response elements (HRE). This will lead to transcription of genes that protect cells 
against hypoxia. [112,114,125] [Figure 8] PHD1, PHD2 and PHD3 have different specificities 
when it comes to hydroxylating HIF-1α, HIF-2α and HIF-3α. [112] Although PHD’s are mainly 
known for their interaction with HIF, it was recently discovered that they have several HIF-
independent functions. Furthermore, it has been hypothesized that the prolyl hydroxylase 
domain proteins are involved in inhibition of IkB kinase (IKK) by hydroxylating it in normoxic 
conditions. Hypoxia inhibits the ability of PHDs to hydroxylate IKK and this leads to activation 
of the NF-κB pathway. [124]  
 
 
Figure 8: The role of prolyl hydroxylase domain proteins PHD1, PHD2 and PHD3 in the degradation of 
Hypoxia-inducible factor (HIF). Adapted from [125] 
In normoxic circumstances the HIF1α concentration in the cell is low because the prolyl hydroxylases will 
hydroxylate HIF1α so it can be degraded in the proteasomes. However, in hypoxic circumstances the ability of 
the HIF prolyl hydroxylases to hydroxylate HIF-α will be inhibited since these enzymes need oxygen as a 
substrate for the hydroxylation to take place. This leads to an increased HIF1α concentration in the cell during 
hypoxic circumstances. HIF-α will translocate to the nucleus, heterodimerize with HIF-β and bind to hypoxia 




A20 and the JAK-STAT pathway: important components of the immune system 
A20, also known as Tumor Necrosis Factor Alpha-Induced Protein 3 (TNFAIP3), has an 
important role in the negative regulation of NF-κB signaling. Interestingly, the expression of 
A20 itself is induced by NF-κB activation, resulting in a negative feedback mechanism to 
control NF-κB dependent inflammation. TNFAIP3 is known to be a susceptibility gene for a 
myriad of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, 
systemic lupus erythematosus, inflammatory bowel disease and psoriasis. [126,127] 
Like NF-κB signaling, Janus kinase-Signal Transducer and Activator of Transcription (JAK-
STAT) signaling has an important role in immune responses. In mammals 4 JAK family 
members (JAK1, JAK2, JAK3 an tyrosine kinase 2 (TYK2)) and 7 STAT (STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B and STAT6) proteins have been identified. Certain polypeptides, 
such as interferon (IFN)-γ, IFN-α/β and IL-6 bind to specific transmembrane receptors, which 
leads to activation of the Janus kinases bound to the receptor. These JAKs then 
phosphorylate tyrosine residues on the receptor, making it possible for specific STATs to 
bind them. The binding between STAT proteins and the intracellular region of the 
transmembrane receptors is specific, enabling the JAK-STAT pathway to exert diverse 
functions. Upon binding, STATs will be phosphorylated and form homo- or heterodimers. 
These dimers will then translocate to the nucleus where they will alter the expression of 
certain target genes. [128,129]  
JAK-STAT signaling is identified to have a major role in the pathogenesis of several immune-
mediated inflammatory diseases. [130] This pathway is known to be involved in both the 
innate and the adaptive immunity. [131] Loss-of function mutations in the genes of the janus 
family kinases can have serious consequences. Both JAK3 and TYK2 deficiency lead to 
primary immunodeficiency. Moreover, mice having a germline deletion of JAK1 or JAK2 are 
not viable. [reviewed in [131]] GWAS studies demonstrated that SNP’s in specific STAT genes 
are involved in the pathogenesis of diverse pathologies. [130] SNP’s in STAT1 for example 
are linked with an increased malignancy risk, SNP’s in STAT3 with psoriasis and crohn’s 





A myriad of cytokines that are important in the pathogenesis of spondyloarthritis or 
rheumatoid arthritis signal through the JAK-STAT pathway. For example, the IL-6 and IL22 
receptor signaling mainly involves JAK1, but JAK2 and TYK2 also associate with these 
receptors. A combination of JAK1 and TYK2 is involved in type I interferon signaling, while 
type II interferon signaling is associated with a combination of JAK1 and JAK2. IL-23 on the 
other hand signals through JAK2 and TYK2. These observations indicate that even though 
only 4 JAK and 7 STAT proteins are identified, distinct signaling occurs by combining these 
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In the last years, substantial progress has been made in characterizing the cytokines and 
signaling involved in the pathogenesis of rheumatoid arthritis and spondyloarthritis. This led 
to the development of important new treatment options in both diseases. However, there 
still are considerable gaps, both in our knowledge of the underlying molecular mechanisms 
as in the available therapeutic options. Two of these gaps being enthesitis and treatment 
options in TNF-α blocker refractory patients. Therefore, our first objective in this PhD project 
was to focus on investigating the JAK-STAT pathway in a TNF-α independent mouse model. 
 
1: Investigation of the pathogenesis of enthesitis  
The aim of this project was to investigate the role of JAK-STAT signaling in mice that had a 
deletion of A20 in the myeloid cells (A20myelKO mice). Since A20myelKO mice develop a 
spontaneous polyarthritis in a TNF-α independent manner [1], this is a suitable model to 
investigate TNF-α independent pathogenic processes. Surprisingly, it was found that 
enthesitis is an early feature of inflammation in these mice. These observations made the 
A20myelKO mouse model even more interesting, because although enthesitis is a hallmark 
feature of spondyloarthritis, the underlying molecular mechanisms remain largely unknown. 
It was previously determined that the pathogenesis of enthesitis is complex and that both T 
cell dependent and independent factors, most likely involving stromal cells, can contribute 
to this process. [2,3] Therefore, the goal of this project was to investigate the 
pathophysiologic process of enthesitis in more detail, using the A20myelKO mouse model and 
to identify proteins that are involved in this process. Bone marrow-derived macrophages 
(BMDMs) were isolated from A20myelKO mice and littermate controls and western blot and 
qPCR analysis were performed to study the effect of A20 on expression of STAT1/STAT3 and 
STAT1/STAT3-dependent gene transcription. Furthermore, the role of JAK-STAT signaling in 
enthesitis development was investigated by administration of a JAK inhibitor or placebo to 




2: To characterize the role of oxygen sensors in the pathogenesis of arthritis 
Moreover, this project aimed to study which factors contribute to chronicity in rheumatic 
diseases. Oxygen supply is an essential requirement for development and homeostasis in all 
eukaryotic cells. However, hypoxia plays a controversial role in the pathogenesis of rheumatic 
disorders: while it is considered a pathogenic factor in arthritis development and can lead to 
NF-κB activation, chronic intermittent hypobaric hypoxia (CIHH) is shown to have a 
protective effect on arthritis in a collagen-induced arthritis (CIA) model in rats, leading to at 
first sight paradoxical results. [4–6] Therefore, our second objective in this PhD project was 
to investigate the role of oxygen supply and oxygen sensors in the pathogenesis of 
rheumatoid arthritis.  
 
The aim of this project was to study the role of hypoxia in more detail by inducing a collagen 
antibody induced arthritis (CAIA) model in DBA/1Rj mice in hypoxia (10% O2) and normoxia 
(21%O2), respectively. It was found that hypoxia protects against arthritis development 
leading us to question what the role of 3 known oxygen sensors: the prolyl hydroxylase 
domain (PHD) proteins is in the pathogenic process of arthritis. Currently, 3 PHD proteins are 
identified: PHD1, PHD2 and PHD3. This project aimed to investigate the role of the individual 
PHD proteins by induction of a CAIA model in germline and even cell specific knock-out mice 
for the specific PHD proteins. Since macrophages are considered important effector cells in 
the CAIA model, mice with a myeloid cell-specific deletion were used. Identifying which PHD 
protein is involved in arthritis development is meaningful because it contributes to our 
knowledge of the pathogenic factors in rheumatoid arthritis and it could potentially lead to 
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A20 is an important endogenous regulator of inflammation. Single nucleotide 
polymorphisms in A20 have been associated with various immune-mediated inflammatory 
diseases, and cell-specific deletion of A20 results in diverse inflammatory phenotypes. Our 
goal was to delineate the underlying mechanisms of joint inflammation in myeloid-specific 
A20-deficient mice (A20myelKO mice). 
Methods 
Inflammation in A20myelKO mice was assessed in a time-dependent manner. Western blot 
analysis and qPCR analysis were performed on bone marrow-derived macrophages from 
A20myelKO and littermate control mice to study the effect of A20 on STAT1/STAT3 expression 
and STAT1/STAT3-dependent gene transcription in myeloid cells. The in vivo role of JAK-STAT 
signaling in the development of enthesitis in A20myelKO mice was assessed following 
administration of a JAK inhibitor versus placebo control. 
Results 
Enthesitis was found to be an early inflammatory lesion in A20myelKO mice. A20 negatively 
modulated STAT1-, but generally not STAT3-dependent gene transcription in myeloid cells by 
suppressing STAT1 but not STAT3 expression, both in unstimulated conditions and after IFN-
γ or IL-6 stimulation. The increase in STAT1 gene transcription in the absence of A20 was 
shown to be JAK-STAT-dependent. Moreover, JAK inhibition in vivo resulted in significant 
reduction of enthesitis, both clinically and histopathologically.  
Conclusions 
Our data reveal an important and novel interplay between myeloid cells and tissue resident 
cells at entheseal sites that is regulated by A20. In the absence of A20, STAT1 but not STAT3 
expression is enhanced leading to STAT1-dependent inflammation. A20 therefore acts as a 
novel endogenous regulator of STAT1 that prevents onset of enthesitis. 




A20, also known as Tumor Necrosis Factor Alpha-Induced Protein 3 (TNFAIP3), is a crucial 
negative regulator of NF-κB-dependent inflammation.[1,2] It has been identified as a 
susceptibility gene for several immune-mediated inflammatory diseases, including 
rheumatoid arthritis, systemic lupus erythematosus and psoriasis.[1,2] Whereas germline 
A20 knock-out (KO) mice die prematurely due to multi-organ inflammation[3], the specific 
function of A20 in different cell types has been extensively studied using conditional knock-
out mice. This showed that A20-deficiency can result in distinct phenotypes, depending on 
the cell type in which A20 is deleted.[1,2] For example, epidermis-specific A20-deficiency 
leads to keratinocyte hyperproliferation, while A20-deficiency in myeloid cells leads to the 
spontaneous development of a progressive arthritis.[4,5] Here, we focused on mice with a 
myeloid cell-specific A20-deficiency, referred to as A20myelKO mice. The inflammation in these 
mice is dependent on Nlrp3 inflammasome activation, interleukin (IL)-6 and IL-1 receptor 
signaling, but independent of TNF.[5,6]  
 
A20 is known to function as a negative regulator of inflammation by restricting NF-κB 
signaling.[1,2] In addition to the NF-κB signaling pathway, the Janus kinase-Signal Transducer 
and Activator of Transcription (JAK-STAT) pathway is also of great importance in the immune 
system.[1,2,7] Given the role of the JAK-STAT pathway in several immune-mediated 
inflammatory disorders[7], we aimed to study the effect of A20 on JAK-STAT signaling in 
myeloid cells. Several cytokines and growth factors are known to signal through the JAK-
STAT pathway[8]; with two prototypic examples: IL-6 and interferon (IFN)-γ. While IFN-γ 
signaling predominantly phosphorylates STAT1, IL-6 signaling strongly phosphorylates 
STAT3.[7,9] Phosphorylated STAT proteins form homo- or heterodimers, followed by nuclear 
translocation and transcriptional activation of their target genes.[8]  
 
Enthesitis is an important hallmark of spondyloarthritis (SpA). A marked characteristic of 
SpA-associated enthesitis is that the inflammation is not confined to the enthesis itself, but 
is also present in the adjacent tissues. Because the synovium and the enthesis are located in 
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close proximity to one another and because there is a functional association between the 
two, they can be regarded as a synovio-entheseal complex (SEC). If microdamage arises in 
the enthesis, this can lead to inflammation of the synovium or even to inflammation of the 
entire SEC.[10,11] Although enthesitis is an important hallmark of SpA, much remains 
unknown about the underlying mechanisms.  
 
A20myelKO mice develop a spontaneous inflammation of the paws.[5] Here we report that 
enthesitis is an early feature of inflammation in these mice. However, it is currently not fully 
understood which molecular events trigger the initial inflammation. Therefore, we aimed to 
delineate the role of A20 in STAT-dependent inflammation by investigating the protein in a 




The generation and phenotypical characterization of A20myelKO mice were previously 
described.[5,6] Detailed information on these mice can be found in the online 
supplementary data. All animal experiments were approved by the local Ethics Committee of 
Laboratory Animal Welfare of Ghent University.  
 
Derivation, culturing and stimulation/treatment of bone marrow-derived macrophages 
(BMDMs) 
BMDMs were derived from bone marrow cells that were isolated by flushing the bone 
marrow of A20myelKO and wild type littermate mice. Cells were cultured for 7 days and 
stimulated/treated on day 8. Detailed information can be found in the online supplementary 




Quantitative polymerase chain reaction (qPCR) analysis 
qPCR analysis was performed on BMDMs that were derived from A20myelKO (n=5) and wild 
type (n=5) littermate mice and stimulated with IL-6 (50ng/ml)[12] or IFN-γ (10ng/ml)[13] for 
0 or 120 minutes. qPCR analysis was also performed on BMDMs that were derived from 
A20myelKO (n=5) mice and treated with tofacitinib citrate (300nM)[14] for  0, 6 or 24 hours. 
Detailed information on the qPCR analysis can be found in the online supplementary data. 
 
Western blot analysis 
Western blot analysis was performed on BMDMs that were derived from A20myelKO (n=9) and 
wild type (n=9) littermate mice and stimulated with IL-6 (50ng/ml)[12] or IFN-γ 
(10ng/ml)[13] for 0, 15, 30, 45, 60, 120 or 240 minutes. Cells were lysed in 200µl E1A lysis 
buffer (50mM Hepes; 50mM Tris [pH 7,4]; 250mM NaCl; 0,1% Nonidet P-40). Actin was used 
as a reference protein to normalize for the amount of protein. Antibody details can be found 
in the online supplementary data. 
 
Luciferase reporter assays 
HEK293T cells were transfected using Ca3(PO4)2 co-precipitation with a total of 1µg DNA 
including a STAT1 or STAT3 luciferase (100ng) reporter plasmid, in the absence or presence 
of wild type A20 (200ng) complementary DNA (cDNA). A β-galactosidase (100ng) plasmid 
was transfected to correct for transfection efficiency. Cells were stimulated for 24h with IL-6 
(50ng/ml)[12] or IFN-γ (10ng/ml)[13] or were left untreated. Detailed information on the 
experiment can be found in the online supplementary data.  
 
Time-dependent assessment of inflammation in A20myelKO mice 
A20myelKO mice (n=45), ranging in age from 10 to 24 weeks, were clinically scored three times 
a week for 3 (n=12) to 4,5 (n=33) weeks. A20myelKO mice with diverse clinical scores (n=22) 
were sacrificed and histology was analyzed. A20fl/flLysMCre+/+ (wild type) mice (n=5) were 
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clinically scored once a week for 3 weeks. Wild type mice (n=5) were sacrificed and histology 
was analyzed.  
 
In vivo assessment of JAK inhibition 
A20myelKO mice with marked clinical inflammation (total clinical score ≥ 1 and < 6) were 
included in the study. They were allocated to treatment based on stratified randomization 
with baseline clinical score and gender as covariates. Mice were treated with tofacitinib 
citrate (50mg/kg body weight, dissolved in 0,5% methyl cellulose; 2% Tween80 in H2O) or 
vehicle without active compound (n=5-6 per group (first experiment), n=9 per group (second 
experiment), n=4 per group (third experiment)). The treatment was given twice daily by 
means of oral gavage. Treatment duration was 14 days in the first experiment; to assess the 
effect of tofacitinib after a longer treatment duration, mice were treated for 21 days in the 
second experiment. The third experiment was a withdrawal study; the treatment was given 
until the difference in clinical inflammation between the placebo treated mice and the 
tofacitinib treated mice was adequate to assess a potential relapse of clinical inflammation 
after treatment discontinuation; treatment duration was 16 days in this experiment. In the 
first two experiments, mice were sacrificed at the end of the treatment period and histology 
was analyzed. In the third experiment, mice were followed up for 1,5 weeks after ending the 
treatment. 
 
Ex vivo assessment of JAK inhibition 
A20myelKO mice were treated with tofacitinib citrate (50 mg/kg b.i.d.) or vehicle without 
active compound (n=4 per group). After 14 days of treatment, the mice were sacrificed and 
cells were isolated from bone marrow and spleen. CD11b positive cells were selected and 
qPCR was performed. Detailed information on the experiments can be found in the online 




Clinical scoring and histology 
Information on clinical scoring and histology can be found in the online supplementary data. 
 
Statistical analysis 
Graphs were made using GraphPad Prism 5 and represent group means ± standard error of 
the mean. Statistical analysis was performed using SPSS Statistics 23. Comparisons between 
two groups were analyzed by means of a two-tailed Mann-Whitney U-Test. Statistical 
significance indicates a p-value < 0,05. Detailed information on the statistical analysis can be 
found in the online supplementary data.  
 
RESULTS 
Enthesitis is an early feature of inflammation in A20myelKO mice  
A20myelKO mice develop a spontaneous paw inflammation.[5] However, the specific site of 
origin of this inflammation is currently unknown. Therefore, A20myelKO mice were evaluated 
over time to assess the onset and evolution of joint inflammation. At the end of the time-
dependent assessment, the incidence of paw inflammation in A20myelKO mice was 78%, with 
the hind paws being predominantly affected. The inflammation of the hind paws occurred 
typically symmetrical (data not shown). Early during arthritis development, A20myelKO mice 
developed swelling in the region of the Achilles tendon, whereas wild type mice were 
macroscopically normal (figures 1A and 1B). In line with this, H&E staining of the ankle 
showed marked inflammation of the SEC in A20myelKO mice, whereas the SEC of wild type 
mice remained histologically normal (figures 2A, 2B, 2C, 2D, 2E, 2F, 2G and 2H). The age at 
which A20myelKO mice developed clinical signs of enthesitis varied between the mice. 
Therefore, mice were classified by clinical and histological score, differentiating between a 
mild, a moderate and a severe stage of inflammation. In the mild stage, clinical inflammation 
was confined to the hindfoot (region of the Achilles tendon and the proximal tarsal region) 
(clinical score ≥ 0,5 and < 1,5) with mild inflammation of the SEC on histology (histological 
score ≥ 0,5 and < 1,5) (figures 2C and 2D). In the moderate stage, clinical inflammation had 
spread to the midfoot and/or the metatarsal region of the paw (clinical score ≥ 1,5 and < 2,5) 
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and/or moderate inflammation of the SEC was observed on histology (histological score ≥ 
1,5 and < 2,5) (figures 2E and 2F). In the severe stage, clinical inflammation was present 
throughout the whole foot (clinical score ≥ 2,5) with severe inflammation of the SEC on 
histology (histological score ≥ 2,5) (figures 2G and 2H). Enthesitis was thus typically seen as 
an early sign of inflammation in A20myelKO mice, preceding the polyarthritis. 
 
 
Figure 1: Enthesitis is an important feature of inflammation in A20myelKO mice  
A: Ankle of a wild type mouse, with no swelling in the region of the Achilles tendon (indicated by an arrow).  






Figure 2: A20myelKO mice have inflammation of the synovio-entheseal complex (SEC) 
A and B: H&E staining of the ankle of a wild type mouse showing no inflammation of the synovio-entheseal 
complex (SEC). (original magnification 10x; the SEC is indicated by an arrow) C and D: H&E staining of the ankle 
of an A20myelKO mouse showing mild inflammation of the SEC, compatible with a mild stage of inflammation. 
(original magnification 10x; the SEC is indicated by an arrow) In this stage, clinical inflammation is confined to 
the hindfoot (region of the Achilles tendon and the proximal tarsal region) (clinical score ≥ 0,5 and < 1,5) with 
mild inflammation of the SEC on histology (histological score ≥ 0,5 and < 1,5). E and F: H&E staining of the ankle 
of an A20myelKO mouse showing moderate inflammation of the SEC, compatible with a moderate stage of 
inflammation. (original magnification 10x; the SEC is indicated by an arrow) In this stage, clinical inflammation 
has spread to the midfoot and/or the metatarsal region of the paw (clinical score ≥ 1,5 and < 2,5) and/or 
moderate inflammation of the SEC can be found on histology (histological score ≥ 1,5 and < 2,5). G and H: H&E 
staining of the ankle of an A20myelKO  mouse showing severe inflammation of the SEC, compatible with a severe 
stage of inflammation. (original magnification 10x; the SEC is indicated by an arrow) In this stage, inflammation 
is present throughout the whole foot (clinical score ≥ 2,5) with severe inflammation of the SEC on histology 




A20 negatively modulates STAT1, but not STAT3 expression  
BMDMs were derived from A20myelKO and wild type littermate mice and stimulated with IFN-
γ or IL-6 to activate the JAK-STAT pathway. Western blot analysis was performed to 
determine STAT1, phosphorylated (P-)STAT1, STAT3 and P-STAT3 protein levels. Since IFN-γ 
signaling mainly phosphorylates STAT1 and IL-6 signaling strongly phosphorylates 
STAT3[7,9], BMDMs were stimulated with IFN-γ to determine the STAT1/P-STAT1 protein 
levels or with IL-6 to determine the STAT3/P-STAT3 protein levels. A20 markedly suppressed 
the basal STAT1 protein levels (figures 3A and 3B). There are 2 alternatively spliced isoforms 
of STAT1 that can both participate in STAT1-dependent immunity: STAT1α and STAT1β.[15] 
Both STAT1α and STAT1β protein levels were suppressed by A20, but the effect was more 
pronounced for STAT1β, leading to a lower STAT1α/STAT1β ratio in the absence of A20 
(figure 3B). The P-STAT1/STAT1 ratio was markedly lower in the absence of A20 (figure 3C). 
A20 had no inhibitory effect on the STAT3 or P-STAT3 protein levels after IL-6 stimulation 
(supplementary figures S1 and S2). The higher STAT1 protein levels in the absence of A20 
could be explained by a suppressive effect of A20 on STAT1 gene transcription: indeed, 
absence of A20 markedly increased STAT1, but not STAT3 gene transcription, both in 
unstimulated conditions and after IFN-γ or IL-6 stimulation, as demonstrated by qPCR 
(figures 3D and 3E). A marked reduction in STAT1 gene transcription was seen after 
treatment of A20-/- BMDMs with tofacitinib, indicating that the JAK-STAT pathway regulates 
the enhanced STAT1 expression in the absence of A20 (figure 3F). To further examine the 
effect of A20 on STAT1/STAT3 expression, we transfected HEK293T cells, that constitutively 
express A20 [16], with a STAT1 or STAT3 luciferase reporter plasmid in the absence or 
presence of wild type A20 cDNA, and stimulated them with IFN-γ or IL-6. In line with the 
previous experiments, A20 suppressed STAT1 promoter activity, but it had no inhibitory 
effect on STAT3 promoter activity (figure 4A and 4B). Since unphosphorylated STAT1 and 
STAT3 are known to function as transcription factors[17,18], STAT1 and STAT3 induced gene 
transcription was analyzed both in unstimulated conditions and after stimulation with IFN-γ 
or IL-6 using qPCR. A considerably higher expression of STAT1 induced genes (CXCL9, CXCL10 
and MX1 [19,20]) was noted in the absence of A20, both in unstimulated conditions and 
after IFN-γ or IL-6 stimulation (figure 5A). There was no distinct effect of A20 on the 
expression of STAT3 induced genes (SOCS3, BCL2L1 and VEGF [21]) in unstimulated 
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conditions or after IFN-γ or IL-6 stimulation, with the exception of a higher SOCS3 expression 






Figure 3: A20 negatively modulates STAT1 expression 
Bone marrow-derived macrophages (BMDMs) were derived from A20myelKO and wild type littermate mice and 
stimulated with interferon (IFN)-γ or interleukin (IL)-6 to activate the JAK-STAT pathway. BMDMs were derived 
from A20myelKO mice and treated with tofacitinib citrate to inhibit the JAK-STAT pathway. Western blot analysis 
was performed to determine STAT1 and P-STAT1 protein levels. qPCR analysis was performed to determine 
transcription levels of STAT1 and STAT3, both in unstimulated conditions and after 2 hours of stimulation with 
IL-6 or IFN-γ. qPCR analysis was also performed to determine STAT1 transcription levels at baseline and after 6 
and 24 hours of treatment with tofacitinib citrate. A: A20-/- BMDMs had markedly higher basal STAT1 protein 
levels compared to A20+/+ BMDMs. (one out of three independent experiments is shown) (n=9 per group for 
the three independent experiments combined) B: Quantification of the STAT1 protein levels on Western blot 
analysis confirmed that A20-/- BMDMs have markedly higher total STAT1, STAT1α and STAT1β protein levels 
compared to A20+/+ BMDMs, both in unstimulated conditions and after IFN-γ stimulation. The STAT1α/STAT1β 
ratio was lower in the absence of A20. C: The P-STAT1/STAT1 ratio was lower in the absence of A20. D: A20-/- 
BMDMs had significantly higher STAT1 gene transcription compared to A20+/+ BMDMs, both in unstimulated 
conditions and 2 hours after IFN-γ or IL-6 stimulation. (n=5 per group) E: A20 had no significant effect on STAT3 
gene transcription in BMDMs in unstimulated conditions or 2 hours after stimulation with IL-6 or IFN-γ. (n=5 
per group) F:  STAT1 gene transcription in A20-/- BMDMs was significantly decreased after 6 and 24 hours of 
tofacitinib citrate treatment compared to untreated A20-/- BMDMs. (n=5) 





Figure 4: A20 negatively modulates STAT1, but not STAT3 promoter activity 
HEK293T cells were transfected with a STAT1 or STAT3 luciferase reporter plasmid, in the absence or presence 
of wild type A20 cDNA. A: Transfection of wild type A20 cDNA in HEK293T cells has an inhibitory effect on the 
STAT1 promoter activity. (results are based on triplicates) B: Transfection of wild type A20 cDNA in HEK293T 
cells had no clear effect on STAT3 promoter activity in unstimulated conditions or after IFN-γ stimulation. There 
was a slight trend towards an enhancing effect of A20 on STAT3 promoter activity after IL-6 stimulation. 
However, since only minor STAT3 luciferase activity could be detected in the experiment, this might not be 




Figure 5: A20 negatively modulates the transcription of STAT1 induced genes, but generally not STAT3 
induced genes 
Bone marrow-derived macrophages (BMDMs) were derived from A20myelKO and wild type littermate mice and 
stimulated with interferon (IFN)-γ or interleukin (IL)-6 to activate the JAK-STAT pathway. Transcription levels of 
STAT1 induced genes (CXCL9, CXCL10, MX1) and STAT3 induced genes (SOCS3, BCL2L1, VEGF) were determined 
by means of qPCR analysis, both in unstimulated conditions and 2 hours after IL-6 or IFN-γ stimulation. A: A20-
/- BMDMs had a significantly higher transcription of STAT1 induced genes compared to A20+/+ BMDMs, both in 
unstimulated conditions and 2 hours after IFN-γ or IL-6 stimulation. (n=5 per group) B: A20 had no distinct 
effect on the transcription of STAT3 induced genes in unstimulated conditions or 2 hours after IL-6 or IFN-γ 
stimulation in myeloid cells, with the exception of a higher SOCS3 gene transcription in A20-/- BMDMs 
compared to A20 +/+ BMDMs in unstimulated conditions.  (n=5 per group)   




Inhibition of JAK-STAT signaling suppresses enthesitis in A20myelKO mice.  
To confirm an in vivo link between A20 and JAK-STAT signaling in the pathogenesis of 
enthesitis in A20myelKO mice, we inhibited JAK-STAT signaling with tofacitinib citrate, an oral 
JAK inhibitor[22]. A20myelKO mice were treated with tofacitinib citrate, dosed orally at 50 
mg/kg twice a day, or with a placebo control, and clinical disease development was assessed. 
A clear reduction in the clinical scores was observed throughout the experiment in the 
tofacitinib citrate treated mice, while the clinical scores of the placebo treated mice 
remained stable over time (figure 6A). Moreover, the clinical scores in tofacitinib citrate 
treated mice increased to the level of the placebo treated mice after discontinuing the 
treatment (online supplementary figure S3). In agreement, histology of the ankles showed 
markedly less inflammation of the SEC in the tofacitinib citrate treated mice compared to 
the placebo treated mice (figures 6B, 6C and 6D), confirming the role of the JAK-STAT 
pathway in the development of enthesitis in vivo. In addition, it was shown by qPCR analysis 
that in vivo tofacitinib treatment reduced the transcription of STAT1 and STAT1-dependent 





Figure 6: Inhibition of JAK-STAT signaling suppresses enthesitis in A20myelKO mice 
A20myelKO mice were treated with tofacitinib citrate (50 mg/kg b.i.d.) or placebo. They were clinically scored 3 
times a week. The mice were sacrificed after the experiment and histology of the ankles was analyzed. A: 
Clinical inflammation clearly diminished throughout the experiment in the tofacitinib citrate treated mice, 
while the clinical scores of the placebo treated mice remained stable over time. Pooled clinical scores of two 
independent experiments are shown (n=14-15 per group). Mice were clinically scored on day 0,2,3,7,9,10 and 
14 in the first experiment and on day 0,2,4,7,9,11 and 14 in the second experiment. B: JAK inhibition attenuates 
histopathological signs of inflammation at the synovio-entheseal complex (SEC): tofacitinib citrate treated mice 
show significantly less inflammation of the SEC compared to placebo treated mice. One out of two independent 
experiments is shown (n=9 per group) C: H&E staining of the ankle of a tofacitinib citrate treated mouse, 
showing few signs of inflammation of the SEC. (magnification 10x; the SEC is indicated by an arrow) D: H&E 
staining of the ankle of a placebo treated mouse, showing clear signs of inflammation of the SEC. 
(magnification 10x; the SEC is indicated by an arrow) E: qPCR analysis of myeloid cells (CD11b positive cells) 
derived from the spleen or bone marrow of tofacitinib citrate or placebo treated A20myelKO mice showed that 
tofacitinib citrate treated mice have a marked reduction in transcription of STAT1 and STAT1-dependent genes 
(CXCL10 and MX1) in the myeloid cells compared to placebo treated mice. (n=4 mice per group; cells were 
pooled per condition) 





In this article, we describe several new and unexpected findings on the inflammatory 
phenotype of A20myelKO mice, which may shed new light on the pathogenesis of enthesitis. 
We show that enthesitis is an early feature of inflammation in A20myelKO mice and that A20 
has an inhibitory effect on STAT1, but not STAT3 expression. Moreover, inhibition of JAK-
STAT signaling significantly reduced enthesitis in the A20myelKO model. These data reveal an 
important link between A20 and JAK-STAT signaling that is necessary for in vivo development 
of enthesitis in the A20myelKO model. In addition, these data show that A20 and STAT1 have 
important roles in the cellular crosstalk between myeloid cells and tissue resident cells in 
enthesitis. These are important new findings contributing to a better understanding of the 
molecular mechanisms behind enthesitis. 
 
A20 has a dual role as regulator of inflammation: it functions as an inhibitor of NF-κB 
signaling[1,2] and we propose that it suppresses STAT1-dependent immune responses 
through downregulating STAT1 expression. We found that A20 negatively modulates STAT1-, 
but not STAT3-dependent gene transcription, suggesting that A20 is able to fine-tune STAT-
dependent inflammation. It is important to note that STAT1 is indispensable for IFN-
mediated immunity and that both STAT1α and STAT1β isoforms can contribute, although 
without being fully redundant.[15] Our data showed that A20 is able to modulate the 
STAT1α/STAT1β ratio, suggesting that A20 could also fine-tune IFN-mediated inflammation. 
These functions may enable A20 to influence the crosstalk between myeloid cells and tissue 
resident cells within joints, making A20 a potent modulator of STAT-mediated inflammation.   
 
In this article, it was demonstrated that A20 has a considerable inhibitory effect on STAT1-, 
but generally not on STAT3-dependent gene transcription in myeloid cells. In hepatocytes, 
A20 was shown to have a negative impact on the SOCS3 expression, leading to enhanced 
and sustained STAT3 phosphorylation by IL-6 and alterations in STAT3-dependent gene 
transcription after liver resection.[23] Our data, however, showed that although SOCS3 
expression was increased in the absence of A20 in unstimulated conditions, there was no 
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distinct effect after IFN-γ or IL-6 stimulation. Moreover, no clear effect of A20 was found on 
STAT3 phosphorylation or on the expression of other STAT3-dependent genes in myeloid 
cells. This difference between the effects of A20 on STAT3 signaling in hepatocytes versus 
myeloid cells can be explained by A20 having cell-specific functions, suggesting that A20 fine-
tunes STAT-dependent immune responses in a cell-specific manner. Our results clearly 
indicate that A20 negatively modulates STAT1 expression and STAT1-dependent gene 
transcription. These results are concordant with recent data showing a suppressive effect of 
A20 on STAT1 expression/signaling in astrocytes and vascular cells.[13,24] Although these 
studies suggest an effect of A20 on STAT1 expression, this is the first report on the impact of 
A20 on myeloid cell function by negatively regulating STAT1 which impacts onset of 
enthesitis. Importantly, our data indicate that STAT1 gene transcription in the absence of 
A20 is JAK-STAT-dependent. This is in line with recent data showing that A20 modulates IFN-
β levels[24], since IFN-β exerts its effect through the JAK-STAT pathway.[8] The inhibitory 
effect of A20 on STAT1 expression in myeloid cells is of major importance since both 
phosphorylated and unphosphorylated STAT1 function as transcription factors.[8,17] A20 
deficiency thus leads to hyperactivation of myeloid cells and this hyperactivation may be an 
important driver of enthesitis development as is shown in A20myelKO mice. The proclivity for 
entheseal disease localization may be related to the repetitive biomechanical strain that is 
put upon the entheses, since it was previously shown that biomechanical stress can drive 
enthesitis in SpA.[25] 
 
The development of enthesitis may occur through several mechanisms: in the A20myelKO 
model, enthesitis clearly originates from myeloid cells, since myeloid cell-specific A20-
deletion leads to the spontaneous development of enthesitis. However, enthesitis can also 
originate from enthesis resident T cells.[26] This process is strongly IL-23-dependent; IL-23 
acts on resident T-cells in the enthesis, leading to IL-22 production.[26] Interestingly, IL-22 
signals through STAT3[26], so JAK-STAT signaling seems to be involved in both experimental 
models of enthesitis even though enthesitis in A20myelKO mice is rather STAT1-dependent. 
These data suggest that, although the initiation of enthesitis may differ substantially and 
could involve both cells of innate and adaptive immunity, it is likely that downstream events 
involve common signaling pathways including JAK-STAT signaling.  
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In summary, our results highlight the dual mode of action of A20 in dampening 
inflammation: A20 functions as an inhibitor of NF-κB signaling[1,2] as well as STAT1-
dependent inflammation. Our data identify A20, STAT1 and JAK-STAT signaling as important 
players in the cellular crosstalk between immune cells and tissue resident cells in 
inflammatory conditions, as seen in enthesitis. Hence, our results support a potential role for 
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A20myelKO model  
A20myelKO mice were generated using the cre-lox system with M lysozyme (LysM) as a 
promotor to have a specific deletion of A20 in myeloid cells.[5] The mice were bred and 
housed in specific pathogen-free conditions in accordance with the general 
recommendations for animal breeding and housing. They were bred in individually 
ventilated cages and the experiments were conducted in conventional cages.  
 
Culturing of bone marrow-derived macrophages (BMDMs)  
BMDMs were cultured for 7 days in 9cm petri dishes (Thermo), using RPMI medium (Gibco 
BRL) containing 10% fetal calf serum, 10units/ml penicillin, 10mg/ml streptomycin, 2mM 
GlutaMAX and 40ng/ml macrophage colony-stimulating factor (M-CSF). On day 3 fresh 
medium was added to maintain a M-CSF concentration of 40ng/ml. The medium was 
refreshed on day 5. The cells were seeded in 6-well plates (Falcon) at a concentration of 
700.000 cells/well on day 7.  
 
Quantitative polymerase chain reaction (qPCR) analysis  
Cells were lysed using RLT lysis buffer (Qiagen) and were kept at -80°C until analysis. RNA 
extraction and cDNA preparation were conducted using the RNeasy mini kit (Qiagen) and the 
QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer’s instructions. 
Each reaction was performed in duplicate. qPCR was performed using a LightCycler 480 
system (Roche) and analyzed using qbase+ (Biogazelle). Respectively β-actin and Rp113a or 
HPRT and Rp113a were used as reference genes.  
 
The following QuantiTect primer assays (Qiagen) were used: CXCL9 (QT00097062), CXCL10 
(QT00093436), MX1 (QT01064231), STAT1 (QT01149519), SOCS3 (QT02488990), BCL2L1 
(QT00149254) and STAT3 (QT00148750).  
 
The following primers for β-actin, HPRT and Rp113a (Invitrogen) and VEGF (Biolegio) were 
used: β-actin Fw: ACCCGCGAGCACAGCTTCTTTG;  
β-actin Rev: GGCCTCGGGAGGGGTTGGTATT; HPRT Fw: TGCTTTCCGGAGCGGTAGCA;  
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HPRT Rev: TCGGCATGACGGGACCGGT; Rp113a Fw: GTGGTCGTACGCTGTGAAGGCATC; 
Rp113a Rev: GGCCTCGGGAGGGGTTGGTATT; VEGF Fw: ACTCGGATGCCGACACGGGA;  
VEGF Rev: CCTGGCCTTGCTTGCTCCCC  
 
Western blot analysis  
The following primary antibodies were used for Western blot analysis: phospho-Stat1 
(Tyr701) (58D6) Rabbit mAb (Cell Signaling Technology), Stat1 (D1K9Y) Rabbit mAb (Cell 
Signaling Technology), Phospho-Stat3 (Tyr705) (3E2) Mouse mAb (Cell Signaling Technology), 
Stat3 (124H6) Mouse mAb (Cell Signaling Technology) and anti-actin mouse mAb (Bio-
Connect)  
 
The following secondary antibodies were used for Western blot analysis: Amersham ECL 
Mouse IgG, HRP-linked whole sheep Ab (GE Healthcare Life Sciences) and Amersham ECL 
Rabbit IgG, HRP-linked whole donkey Ab (GE Healthcare Life Sciences)  
 
The primary antibodies for STAT1 and P-STAT1 can recognize both (P-)STAT1α and (P-STAT1β 
isoforms. 
 
Luciferase reporter assays  
HEK293T cells were a gift from Dr. M. Hall (Department of Biochemistry, University of 
Birmingham, UK) as described by Verhelst et al.[16] These cells were seeded in 6-well plates 
at a concentration of 200.000cells/well and incubated at 37°C with 5% CO2. After 24h of 
culture, cells were transfected using Ca3(PO4)2 co-precipitation with a total of 1μg DNA 
including a STAT1 or STAT3 luciferase (100ng) reporter plasmid, in the absence or presence 
of wild type A20 (200ng) cDNA. A β-galactosidase (100ng) plasmid was transfected to correct 
for transfection efficiency. After 8h of incubation, the medium was refreshed and the cells 
were grown overnight. Cells were stimulated for 24h with IL-6 (50ng/ml)[12] or IFN-γ 
(10ng/ml)[13] or were left untreated. Cells were lysed in luciferase lysis buffer (25mM Tris 
phosphate pH 7,8; 2mM DTT; 2mM CDTA (1,2 diaminocyclohexane-N.N.N.N-tetraacetic 
acid); 10% glycerol; 1% Triton X-100) and luciferase activity was determined by adding 50μl 
of lysate to 30μl luciferase buffer (20mM Tricine; 1,07mM (MgCO3)4Mg(OH)2.H2O; 2,67mM 
MgSO4; 33,3mM DTT; 0,1mM EDTA; 270μM CoA; 530μM ATP; 470μM Luciferin). Luciferase 
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activity was measured with the GloMax 96 Microplate Luminometer (Promega) for 5 seconds 
per well. β-galactosidase activity was determined by means of CPRG (Sigma Aldrich) in CPRG 
substrate buffer (60mM Na2HPO4; 10mM KCl; 1mM β-mercaptoethanol).  
 
pACTbgal (LMBP4341), which contains a β-galactosidase gene after the β-actin promoter, 
was from Dr. J. Inoue (Institute of Medical Sciences, Tokyo, Japan) as described by Verhelst 
et al.[16]  
 
pCAGGSEhA20 (LMBP3778) was previously described by Verhelst et al.[16]  
 
Ex vivo assessment of JAK inhibition  
A20myelKO mice with marked clinical inflammation (total clinical score ≥ 1 and < 6) were 
included in the study. They were allocated to treatment based on stratified randomization 
with baseline clinical score and gender as covariates. Mice were treated twice a day with 
tofacitinib citrate (50 mg/kg body weight, dissolved in 0,5% methyl cellulose; 2% Tween80 in 
H2O) or vehicle without active compound (n=4 per group). Mice were treated for 14 days, 
since previous experiments showed that there was already a marked effect of tofacitinib 
citrate after 14 days of treatment. On day 14 the mice were sacrificed and cells were isolated 
from the bone marrow and the spleen.  
 
Single cell suspensions from the spleen were resuspended in PBS containing 1mM EDTA and 
0,5% BSA and layered over Ficoll gradients. Bone marrow cells were flushed from the femur 
and tibia, treated with ACK lysis buffer and resuspended in PBS containing 1mM EDTA and 
0,5% BSA. CD11b+ cells were positively selected using mouse CD11b Microbeads (Miltenyi 
Biotech) and MS-MACS columns (Miltenyi Biotech).  
 
The cells were incubated in 0,5 μg FcR Block (Miltenyi Biotech) for 10 minutes at RT. Surface 
staining was performed in the dark for 30 minutes at 4°C in staining buffer. Cells were then 
washed twice with staining buffer and were sorted on FACS Aria II (BD Biosciences). The 
following antibodies were used: CD19-eFlour-450 (eBioID3), CD11c-PE-Cy7 (N418), NK1.1-PE 
(PK136), CD11b-APC (M1/70), CD4-V500 (RM4-5), CD8a-V500 (53-6.7), Ly6c-Alexa Flour-488 
(HK 1.1) and Ly6G (Gr-1)-PE- Cyanine5.5 (RB6-8C5) (all from eBioscience). After exclusion of 
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debris, doublets, nonviable cells and lineage markers (CD4, CD8, CD19, NK1.1, CD11cHi), 
monocytes and macrophages were sorted as a CD11b+ Ly6CLo-negLy6G- SSCLo population.  
 
Clinical scoring and histology:  
A20myelKO mice were clinically scored three times a week to evaluate the degree of 
inflammation in the paws. Clinical scoring was performed by a blinded assessor. Each paw 
was scored individually and received a score ranging from 0 (normal) to 3, resulting in a 
maximum score of 12 for each mouse. Paws received a score of 1 if the ankle/wrist region 
was inflamed, they received an extra point if the metatarsal/metacarpal region was inflamed 
and another 0,5 or 1 point if respectively one or more fingers/toes were inflamed. In case of 
doubt between 2 scores, the mean value was given.  
 
After sacrificing the A20myelKO mice, the hind paws were isolated and fixed in 4% 
formaldehyde for 24 hours. Ankle joints were decalcified in 5% formic acid for 7 days and 
embedded in paraffin. Paraffin sections of the ankle were stained with hematoxylin and 
eosin (H&E) to evaluate inflammation of the synovio-entheseal complex (SEC). Histology was 
scored by two blinded assessors; scores ranged from 0 (normal) to 3. A score of 1 was given 
for mild inflammation of the SEC, a score of 2 was given for moderate inflammation of the 
SEC and a score of 3 was given for severe inflammation of the SEC. In case of doubt between 
2 scores, the mean value was given.  
 
Statistical analysis  
To compare the evolution of clinical scores between two groups, delta values were 
calculated by subtracting the clinical score at the end of the experiment from the score at 
day 0. A two-tailed Mann-Whitney U-Test was conducted on these delta values.  
 
During the in vivo tofacitinib experiments 1 placebo treated and 1 tofacitinib treated mouse 
died; the clinical scores of these mice were excluded and no histology was performed on 
these mice. 1 A20myelKO mouse died during the time-dependent assessment; the clinical 




Supplementary figure 1: A20 does not negatively modulate STAT3 expression 
Bone marrow-derived macrophages (BMDMs) were derived from A20myelKO and wild type littermate mice and 
stimulated with interleukin (IL)-6 to activate the JAK-STAT pathway. Western blot analysis was performed to 
determine STAT3 protein levels. A20 did not have an inhibitory effect on STAT3 protein levels in BMDMs. (one 






Supplementary figure 2: Effect of A20 on STAT3 phosphorylation status 
Bone marrow-derived macrophages (BMDMs) were derived from A20myelKO and wild type littermate mice and 
stimulated with interleukin (IL)-6 to activate the JAK-STAT pathway. Western blot analysis was performed to 
determine P-STAT3 protein levels. A20 did not have an inhibitory effect on P-STAT3 protein levels in BMDMs. 






Supplementary figure 3: Continued administration of tofacitinib is needed to treat enthesitis in A20myelKO 
mice: results from a withdrawal study 
A20myelKO mice were treated with tofacitinib citrate (50mg/kg, b.i.d.) or placebo control for 16 days. The mice 
were clinically scored three times a week during the treatment and during 9 days after discontinuation of the 
treatment. Clinical scores were shown as the mean of two consecutive clinical scoring time points. During the 
treatment period, clinical inflammation diminished in the tofacitinib citrate treated mice, while the clinical 
scores of the placebo treated mice increased over time. After discontinuing the treatment, the clinical scores of 
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Oxygen supply is a vital process for all eukaryotic species and is controlled by dedicated 
sensors; yet surprisingly little is known on their contribution to arthritis. We therefore 
explored the role of oxygen sensors PHD1, PHD2 and PHD3 in arthritis development, and 
investigated the responsible cellular source. 
Methods 
Collagen antibody-induced arthritis (CAIA) was induced in hypoxic (10% O2) versus normoxic 
(21% O2) conditions, in mice with germline deficiency of specific PHD isoforms and in mice 
with a myeloid cell-specific Phd1 deficiency versus littermate controls. Arthritis development 
was assessed by clinical scoring of paw swelling, histopathology and µCT.  
Results  
We demonstrated that hypoxia and germline Phd1 deletion strongly protect against arthritis 
development. Moreover, Phd1-/- mice were also protected against inflammation-induced 
bone loss. By contrast, no difference in clinical arthritis was found between Phd2 
heterozygous (Phd2-/- mice are not viable) or Phd3-/- mice and littermate controls. Because 
myeloid cells are considered critical effector cells in CAIA, myeloid cell-specific Phd1-/- mice 
were examined. Interestingly, these mice developed less arthritis and inflammation-induced 
bone loss compared with littermate controls. 
Conclusions 
Our data indicate that the oxygen sensor PHD1 is a critical regulator of arthritis development 
and a potential target in the treatment of arthritis.  
 





Oxygen is a fundamental requirement for development and homeostasis in all eukaryotic 
cells. Interestingly, articular joints are characterized by a hypoxic state compared with other 
tissues and this feature becomes even more pronounced in inflamed joints.[reviewed in [1]] 
Although the intriguing link between hypoxia and inflammation has been recognized for 
years, the underlying molecular mechanisms remain poorly understood. While hypoxia is 
considered a pathogenic factor in arthritis development, chronic intermittent hypobaric 
hypoxia (CIHH) for example has been shown to have a protective effect on arthritis in a 
collagen-induced arthritis (CIA) model in rats, leading to at first sight paradoxical results.[1–
3] Our goal was to examine the role of hypoxia in the pathogenesis of arthritis in more detail 
by investigating the role of 3 oxygen-sensitive prolyl hydroxylase domain (PHD) proteins 
PHD1, PHD2 and PHD3.  
 
These enzymes, whose hydroxylase activity is essentially controlled by oxygen, are well-
known for their role in Hypoxia Inducible Factor-α (HIF-α) degradation.[4–6] However, 
recent observations indicate that they also display HIF-independent functions, including 
regulation of mTOR, NF-κB, apoptosis and cell metabolism.[6] PHD1, PHD2 and PHD3 have 
distinct expression patterns and all of them have been ascribed specific roles in a myriad of 
biological processes.[6,7] While germline Phd1 deficiency leads to an increased tolerance for 
hypoxia, conditional Phd2 deficiency results in polycythemia, congestive heart failure, 
hyperactive angiogenesis and angiectasia, and germline Phd3 deficiency causes hypotension 
and abnormal sympathoadrenal development.[5,8–12] It could be anticipated that each PHD 
protein could be of importance in the pathogenesis of rheumatoid arthritis (RA). While it was 
demonstrated that PHD1 plays an important role in colitis development[13,14], PHD2 was 
shown to be the PHD isotype with the most pronounced impact on the HIF-concentration in 
RA fibroblast-like synoviocytes and is suggested to play an important role in RA, however this 
was solely based on in vitro data.[10] PHD3, on the other hand, has a role in neutrophil 
survival during inflammation and it characterizes pro-inflammatory macrophages.[15,16] 
However, to date no studies have been performed investigating their in vivo role in 





Detailed information on the mice can be found in the online supplementary data. All animal 
experiments were approved by the local Ethics Committee of Laboratory Animal Welfare of 
Ghent University. 
 
Collagen antibody-induced arthritis model 
Collagen antibody-induced arthritis (CAIA) was induced using ArthritoMab antibody cocktail 
(MDBiosciences: CIA-MAB-50 (DBA1/Rj mice) or CIA-MAB-2C (C57BL/6 mice)) and 
lipopolysaccharide (LPS) (MDBiosciences) according to the manufacturer’s instructions, save 
sacrificing the mice on day 14 instead of day 12.  Mice were clinically scored on a daily basis, 
starting at day 3 until the end of the experiment. Detailed information on the clinical scoring 
system can be found in the online supplementary data.  
 
Hypoxia chamber 
Mice were kept in hypoxic conditions (10%O2) starting 3 days prior to CAIA induction using a 
hypoxia chamber. They were housed in hypoxia during the entire experiment and were only 
taken out of the chamber for administration of the antibody cocktail and LPS and for 
assessment of clinical signs. The mice in the control group were kept in normoxic conditions 
(approximately 21%O2) in the same room.  
 
Histology and µCT-scans 
Detailed information on the histology, histological scoring, µCT-scans and their analysis can 
be found in the online supplementary data.  
 
Statistical analysis 







Hypoxia protects against arthritis development 
To investigate the effect of continuous hypoxia on arthritis development, a CAIA model was 
induced in DBA/1Rj mice that were kept in normoxic or hypoxic conditions. Mice in the 
hypoxia group were housed in a hypoxia chamber (10% O2) starting 3 days prior to CAIA 
induction until the end of the experiment. Interestingly, mice kept in hypoxic conditions 
developed significantly less arthritis compared to mice in normoxia.[Fig1A] These 
observations were confirmed on histology: mice in hypoxic conditions had significantly less 
cartilage destruction, infiltrate, exudate and bone erosions and a strong trend towards less 





Figure 1: Hypoxia protects against collagen antibody-induced arthritis (CAIA) 
CAIA was induced in DBA/1Rj mice in hypoxic (10% O2) and normoxic (21% O2) conditions, respectively. A: Mice 
kept in hypoxia showed significantly less clinical inflammation compared to mice in normoxic conditions. (n=38 
per group) Because our goal was to study differences in clinical scores between the groups when arthritis was 
present, only time points at which the mice kept in normoxic conditions exhibited a clinical score ≥ 1,5 were 
included in the statistical analysis. B: Safranin staining in a mouse kept in normoxic conditions, showing 
pronounced inflammation of the knee joint. (magnification 4x) C: Safranin staining in a mouse kept in hypoxic 
conditions, showing few signs of inflammation of the knee joint. (magnification 4x) D: Mice kept in hypoxia 
showed significantly less cartilage destruction, exudate, infiltrate and erosions compared to mice in normoxic 
conditions. There also was a strong trend towards less proteoglycan depletion. (n=35-36 per group) 




PHD1 deficiency protects against arthritis development 
To study the protective effect of hypoxia on arthritis development in more detail, we 
investigated the role of the individual oxygen sensors PHD1, PHD2 and PHD3 in the 
pathogenesis of arthritis. Therefore, a CAIA model was induced in mice with germline 
deficiencies of the individual PHD enzymes. Germline Phd1 knock-out (Phd1-/-) mice showed 
markedly less inflammation than littermate control (Phd1+/+) mice, both clinically and 
histopathologically.[Fig2A,B,C and D] Because the CAIA model induces loss of trabecular 
bone mass [17], µCT-scans were performed at UGCT to quantify the bone mass in these 
mice. The µCT-scans demonstrated that Phd1-/- mice had a significantly higher trabecular 




Figure 2: Germline Phd1 deletion protects against collagen-antibody induced arthritis (CAIA) 
CAIA model was induced in Phd1-/- and Phd1+/+ mice. A: Phd1-/- mice showed significantly less clinical 
inflammation compared to Phd1+/+ mice. (n=16-21 per group) Because our goal was to study differences in 
clinical scores between the groups when arthritis was present, only time points at which the wildtype mice 
exhibited a clinical score ≥ 1,5 were included in the statistical analysis. B: Safranin staining of a Phd1+/+ mouse, 
showing clear inflammation of the knee joint. (magnification 4x) C: Safranin staining of a Phd1-/- mouse, 
showing few signs of inflammation of the knee joint. (magnification 4x) D: Phd1-/- mice showed significantly less 
proteoglycan depletion, cartilage destruction, exudate, infiltrate and erosions compared to Phd1+/+ mice.  
(n=12-18 per group) 




Investigating the function of PHD2 is complicated by the fact that germline Phd2 knock-out 
mice are not viable.[18] To study the role of Phd2 in arthritis development, a CAIA model 
was induced in germline Phd2 heterozygous (Phd2-/+) and littermate control (Phd2+/+) mice. 
There was no difference in the amount of clinical arthritis between Phd2-/+ and Phd2+/+ 
mice.[Supplementary FigureS2A] Since clinical arthritis is the most relevant parameter in this 
model, no further examinations were performed on these mice.  
 
The role of PHD3 in the pathogenesis of arthritis was investigated by inducing a CAIA model 
in germline Phd3 knock-out (Phd3-/-) and littermate control (Phd3+/+) mice. No difference in 
the amount of clinical inflammation was seen between Phd3-/- and Phd3+/+ mice, indicating 
that PHD3 does not have an important role in arthritis development.[Supplementary 
FigureS2B]  
 
Since macrophages are considered important effector cells in the CAIA model, the in vivo 
role of PHD1 in myeloid cells was investigated by generating mice with a myeloid cell-specific 
deletion of Phd1 (Phd1myelKO) and subjecting them to CAIA. Phd1myelKOmice showed 
significantly less clinical arthritis compared to littermate controls.[Fig3A] Furthermore, they 
also exhibited a significantly higher trabecular bone mass and significantly less infiltrate on 
histology.[Fig3B,C,D and Supplementary FigureS3] There was a trend towards less 
proteoglycan depletion, cartilage destruction, exudate and erosions in Phd1myelKOmice versus 





Figure 3: Myeloid cell-specific Phd1 deletion protects against collagen-antibody induced arthritis (CAIA) 
CAIA was induced in Phd1myelKO mice versus littermate controls. A: Phd1myelKO mice showed significantly less 
clinical inflammation compared to controls. (n=19-20 per group) Because our goal was to study differences in 
clinical scores between the groups when arthritis was present only time points at which the wildtype mice 
exhibited a clinical score ≥ 1,5 were included in the statistical analysis. B: Safranin staining of a wildtype mouse, 
showing clear inflammation of the knee joint. (magnification 4x) C: Safranin staining of a Phd1myelKO mouse, 
showing few signs of inflammation of the knee joint. (magnification 4x) D: Phd1myelKO mice showed significantly 
less infiltrate compared to littermate controls. There also was a strong trend towards less proteoglycan 
depletion, cartilage destruction, exudate and erosions, but this did not reach statistical significance.   (n=18 per 
group) 





Here we provide several novel and unexpected findings on the role of PHD1 in the 
pathogenesis of arthritis. We demonstrate that hypoxia strongly protects against arthritis 
development. Since hypoxia inhibits the function of PHD proteins, we investigated their 
contribution to arthritis development in the same preclinical model. We could clearly 
demonstrate that loss of Phd1, and not Phd2 or Phd3, provides protection from arthritis 
development. In addition, Phd1 deletion also protects against inflammation-induced bone 
loss. Myeloid cells are considered critical effector cells upon passive transfer of arthritogenic 
antibodies in the CAIA model; we therefore investigated the role of PHD1 specifically in 
myeloid cells during arthritis development. Accordingly, Phd1myelKO mice developed less 
arthritis and inflammation-induced bone loss versus littermate controls. Overall, the data are 
consistent with a model in which PHD1 has a major role in regulating inflammatory features 
of myeloid cells during arthritis development and suggest a potential role for PHD1 as a 
therapeutic target in RA.  
 
Of interest, our data are in line with results from mouse experimental colitis models.[13,14] 
There, Phd1 deletion in bone-marrow derived macrophages was demonstrated to skew 
these cells towards an anti-inflammatory M2 phenotype and led to increased basal NF-κB 
activation, but a less potent NF-κB-dependent response after LPS stimulation.[14] This 
suggests a role for PHD1 in restricting endotoxin tolerance responses, which can explain the 
protection of Phd1-/- mice from CAIA where LPS stimulation is required to boost arthritis 
development. Thus, during arthritis development, PHD1 may act as a regulator of TLR-4 
mediated activation of NF-κB which drives inflammatory responses. Whether a similar role 
for PHD1 in regulating responses against other TLR ligands, including danger associated 
molecular patterns (DAMPs) that may be released during joint inflammation (e.g. S100 
proteins) remains to be determined.  
 
A surprising finding was the selective role for PHD1 versus PHD2 or -3. A recent study 
suggests that PHD2 is the PHD isotype with the most pronounced impact on the HIF-
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concentration in RA fibroblast-like synoviocytes and that this isotype plays an important role 
in RA based on in vitro data.[19] However, our data did not show a clear difference in clinical 
arthritis scores between Phd2 -/+ and Phd2+/+ mice. This could be indicative of PHD2 not 
having an important role in arthritis development. However, our studies were limited by the 
necessity to work with Phd2-/+ instead of Phd2-/- mice, since the latter are not viable. In 
addition, PHD2 could contribute to arthritis in multiple cell types such as for example 
stromal cells. Future studies using conditional and/or cell-specific deletion of Phd2 should 
shed light on their involvement. It should be underscored that PHD enzymes exert both HIF-
dependent and HIF-independent functions. Since PHD1 has an important function 
modulating activation of  NF-κB[14], it is likely that this is responsible for the arthritis 
protective role of PHD1 deletion. There are reports that the effect of PHD1 on NF-κB 
activation in hypoxia occurs independently of HIF1α.[20] Overall, our data suggest a crucial 
role for PhD1 in controlling myeloid cell function during arthritis development. 
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DBA/1Rj mice from Janvier were used for the hypoxia chamber experiments. Phd1-/-, Phd2+/-, 
Phd3-/-, Phd1+/+, Phd2+/+ and Phd3+/+ mice were bred on a C57BL/6 background. Phd1fl/fl 
LysMCreTg/wt (Phd1myelKO) and Phd1fl/fl LysMCrewt/wt mice were generated on a C57BL/6 
background. The mice were bred and housed in specific pathogen-free conditions in 
accordance with the general recommendations for animal breeding and housing. Breeding of 
the mice was conducted in individually ventilated cages and experiments were performed in 
conventional cages.  
 
Clinical scoring 
Each paw was scored individually and received a score ranging from 0 (normal) to 4, 
resulting in a maximum score of 16 for each mouse. Paws received a score of 1 if the 
ankle/wrist region was edematous, they received an extra point if the 
metatarsal/metacarpal region was swollen and another 0,5 or 1 point if respectively one or 
more digits were edematous. A score of 4 was given in case the digits had severe 
deformation leading to incapacitation of the limb.  
 
Histology 
After sacrificing the mice, the hind paws were isolated and fixed in 4% formaldehyde for 24 
hours. Knee joints were decalcified in 5% formic acid for 7 days and embedded in paraffin. 
Paraffin sections of the knee were stained with hematoxylin and eosin (H&E) to evaluate 
infiltrate, exudate and erosions and with safranin O-fast green to evaluate proteoglycan 
depletion and cartilage destruction. Histology was scored by two blinded assessors for 
proteoglycan depletion, cartilage destruction, infiltrate, exudate and erosions separately. For 
the hypoxia chamber and the conditional Phd1 deletion experiments both the tibio-femoral 
joint and the patella-femoral joint were scored; a mean score of both joints was calculated. 
Due to technical issues, histology of the germline Phd1-/- experiments was scored based on 




Histological inflammation was assessed by scoring five parameters: exudate and infiltrate 
were scored on a scale of 0 (no inflammation) to 4 (severely inflamed joint). Proteoglycan 
depletion was scored on a scale of 0 (fully stained cartilage) to 3 (destained cartilage or 
complete loss of cartilage). Cartilage destruction was scored on a scale of 0 (normal 
cartilage) to 3 (complete loss of the cartilage). Erosions were scored on a scale of 0 (no 
erosions) to 4 (large amount of erosions penetrating the cortex).  
 
µCT-scans 
After sacrificing the mice, the hind paws were isolated and fixed in 4% formaldehyde for 24 
hours. They were then kept in 70% ethanol until µCT-scans of the tibia were conducted. The 
tibia were scanned with the High-Energy CT system Optimized for Research (HECTOR) [1] of 
the Centre for X-ray Tomography of the Ghent University (UGCT, www.ugct.ugent.be). The 
directional X-ray source was set at 130 kV tube high voltage and 10-Watt beam power with a 
1 mm Aluminium filtration. The detector was a Perkin-Elmer flat panel. A total of 2000 
projections of 1 second exposure time each was recorded per scan. The resulting scan 
images have a voxel size of 4 micrometre. 
 
A standardized region of the tibia was analyzed using a custom script in ImageJ that 
automatically classifies the bone structures within this region using an algorithm similar to 
that of Buie et al.[2] For quantification purposes the entire volume (determined by the 
number of voxels) of these structures was measured. Using this methodology measures 




Differences in histological scores and µCT values between two groups were tested using a 
Mann-Whitney U-Test (SPSS Statistics 24). Clinical scores were analyzed as repeated 
measurements using the restricted maximum likelihood (REML) approach as implemented in 
Genstat v18.[3] Briefly, a linear mixed model with genotype, time and genotype  time 
interaction as fixed terms, replicate (n=2) as random term and subject.time used as residual 
term, was fitted to data. Times of measurement were set at equal intervals and the 
unstructured correlation structure was selected as best model fit based on the Aikake 
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Information Coefficient. Significances of the fixed terms were assessed by an F-test. Because 
our focus was on the differences in clinical scores between the two groups when mice 
exhibited significant inflammation, only time points at which the control mice exhibit a 
clinical score ≥ 1.5 were included in the repeated measurements analysis. Graphs 
representing the mean ± se (standard error of the mean) were made using GraphPad Prism 
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Supplementary figure 1: Germline Phd1 deletion protects against inflammation-induced bone loss 
CAIA model was induced in Phd1-/- and Phd1+/+ mice and the mice were subjected to µCT. A: Trabeculae of a 
Phd1+/+ mouse, showing clear trabecular bone loss. B: Trabeculae of a Phd1-/- mouse with few signs of 
trabecular bone loss. C: Phd1-/- mice have a significantly higher trabecular bone mass (relative to the total 
volume) compared to Phd1+/+ mice. (n= 7-10 per group) D: The cortical bone mass (relative to the total volume) 
is not different between Phd1-/- and Phd1+/+ mice. (n= 7-10 per group) 





Supplementary figure 2: No difference in arthritis development between Phd2 heterozygous or Phd3 knock-
out mice and littermate controls 
A: CAIA induced in Phd2-/+ (Phd2-/- mice are not viable) and Phd2+/+ mice. There is no clear difference in clinical 
arthritis between Phd2+/- and Phd2+/+ mice.  (n=19-22 per group) 
B: CAIA induced in Phd3-/- and Phd3+/+ mice. No difference in clinical arthritis between Phd3-/- and Phd3+/+ mice 





Supplementary figure 3: Myeloid cell-specific Phd1 deletion protects against inflammation-induced bone loss 
CAIA model was induced in Phd1myelKO mice versus littermate controls and these mice were subjected to µCT. A: 
Trabeculae of a littermate control show clear trabecular bone loss. B Trabeculae of a Phd1myelKO mouse show 
few signs of trabecular bone loss. C: Phd1myelKO  mice have a significantly higher trabecular bone mass (relative 
to the total volume) compared to controls. (n= 9-11 per group) D: The cortical bone mass (relative to the total 
volume) is not different between Phd1myelKO mice and controls. (n= 9-11 per group) 
























GENERAL DISCUSSION AND CONCLUSIONS 
Both rheumatoid arthritis and spondyloarthritis are prevalent chronic rheumatic disorders, 
that can (and in the case of spondyloarthritis even mainly) affect young people. The current 
therapies can bring the disease in remission, but at present rheumatoid arthritis and 
spondyloarthritis cannot be cured (yet). This means that patients have to be treated for 
many years, sometimes even during the major part of their life using medication that 
modulates their immune system. In chronic therapies, it is even more important to use 
medication with a good benefit-risk profile both on the short time and after years of 
treatment. The best way to obtain an appropriate benefit-risk profile is to target the immune 
system as specifically as possible.  
 
At the moment, the first-line therapies in both the treatment of rheumatoid arthritis and 
spondyloarthritis are not targeted to specific proteins involved in the pathogenesis of the 
disease, but have a rather broad effect on the immune system. Examples of these first-line 
therapies are methotrexate, NSAIDs, glucocorticoids, leflunomide and sulfasalazine. The 
first-choice biological in both rheumatoid arthritis, spondyloarthritis and several other 
immune-mediated inflammatory diseases (IMIDs) specifically targets TNF-α.  Interestingly, 
TNF-α blocking agents are a targeted therapy, and the fact that this therapy is very 
efficacious in the treatment of rheumatic arthritis and spondyloarthritis indicates that broad 
modulation of the immune system is not necessary to successfully treat these diseases.[1] It 
is hypothesized that a cytokine hierarchy characterizes rheumatic disorders and explains the 
different efficacies of several treatment in distinct IMIDs. While some cytokine pathways are 
shared between these diseases, other pathways are more private. [1] There is an important 
need in the treatment of IMIDs and rheumatic diseases in particular for specific targeted 
therapies that will minimize the risk of adverse effect while having a good efficacy at the 
same time.  
 
The goal of our project was to study the pathophysiology of arthritis and/or enthesitis by 
focusing on new pathways (JAK-STAT and hypoxia) that could function as potential 




In chapter 3 A20 (Tumor Necrosis Factor-α Induced Protein 3) was identified as an important 
regulator of myeloid cell biology in the pathogenesis of enthesitis in mice that have a 
myeloid cell-specific deletion of A20 (A20myelKO mice). It was shown that deletion of A20 in 
myeloid cells leads to an increased expression of STAT1, where this results in the 
spontaneous development of enthesitis. This inflammation is STAT1-dependent and the 
STAT1 expression in this mouse model is JAK-STAT dependent. Unexpectedly, a direct link 
between A20 and STAT1 expression could be unraveled. Overall, this article identifies several 
potential therapeutic targets for the treatment of enthesitis.  
 
First of all, enhancement of A20 expression and/or activity is identified as a potential 
therapeutic option. A20 has a dual role as regulator of inflammation: it functions as an 
inhibitor of NF-κB signaling [2,3] and our data demonstrated that it suppresses STAT1-
dependent immune responses through downregulating STAT1 expression. It is important to 
note that STAT1 is indispensable for IFN-mediated immunity and that both STAT1α and 
STAT1β isoforms can contribute, although without being fully redundant.[4] Our data show 
that A20 is able to modulate the STAT1α/STAT1β ratio, suggesting that A20 could also fine-
tune IFN-mediated inflammation. Overall, enhancement of A20 expression and/or activity 
would prevent/reduce hyperactivity of macrophages. Interestingly, GWAS studies 
demonstrated A20 to be a susceptibility gene in a myriad of IMIDs, such as rheumatoid 
arthritis, psoriasis, diabetes mellitus type 1, systemic lupus erythematosus, inflammatory 
bowel disease and many others indicating that therapies targeting A20 could be useful in a 
broad range of pathologies. [2,3] 
 
These data suggest A20 to be a very attractive target protein in the treatment of rheumatic 
disease such as spondyloarthritis, but further investigation to determine the efficacy of 
specific enhancement of A20 expression/activity and the potential adverse events is 
necessary. However, to our knowledge, no therapies specifically targeting A20 expression 
and/or activity are currently available. Interestingly, A20 expression is induced by TNF-α 
signaling [3], implicating that TNF-α blockers would actually decrease the expression of A20. 
However, A20 inhibits NF-κB activation by TNF providing a negative feedback loop to prevent 
excessive TNF/NF-κB signaling. [3] This is confirmed by data showing that A20 deficient mice 
are hypersensitive to TNF stimulation resulting in premature lethality in these mice. [5] 
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These data implicate that enhancing A20 expression or activity would be useful in TNF-α 
dependent inflammation, while our data indicate also a benefit in TNF-α independent 
arthritis. However, it is important to keep in mind that A20 exhibits cell specific functions. 
For example, while it has clear anti-apoptotic properties in various cell types, it 
demonstrates pro-apoptotic effects in other cell types, most likely by inhibiting the NF-κB 
dependent expression of anti-apoptotic genes. [3] Since our data demonstrated that it is A20 
deficiency in myeloid cells that results in STAT1 dependent enthesitis, specific targeting of 
A20 in the myeloid cells would increase the changes of obtaining an appropriate benefit-risk 
balance.  
 
Interestingly, MALT1 is known to modulate the inhibitory effect of A20 on NF-κB activation 
by cleaving the protein [6], indicating that a potential strategy to enhance A20 activity would 
be inhibition of MALT-1. Another potential treatment option would be enhancing the IKK-β 
activity. Although this protein is known to function as a potent activator of NF-κB signaling, 
IKK-β is able to phosphorylate A20 and enhance its inhibitory activity on the NF-κB 
activation, providing a negative feedback loop to prevent excessive NF-κB signaling. [7] 
However, even though theoretically speaking enhancing IKK-β activity could be a potential 
therapeutic target, the enhancing effect of IKK-β on NF-κB activation appears to overrule the 
enhancing effect on A20 activity, since several IKK inhibitors have been developed and it is 
suggested after investigating these inhibitors in preclinical models that IKK inhibition may be 
of benefit in inflammatory and auto-immune diseases.[8] These data indicate, that although 
IKK-β can provoke a negative feedback loop by phosphorylation of A20, enhancing IKK-β 
activity would not be a suitable treatment option. A20 binding to specific binding partners is 
important for the activity of A20, making these proteins potential targets to modulate A20 
activity as well. [3] A fourth potential strategy could be targeting of certain micro RNAs, since 
they were shown to enhance NF-κB signaling by suppressing A20 expression. [9] In summary, 
it can be stated that there are several potential treatment strategies to influence A20 activity 
or expression and further investigation of these options appears to be worthwhile, although 





A more specific target in the pathogenesis of enthesitis would be inhibition of STAT1 
expression. Given the fact that unphosphorylated STAT1 is able to function as a transcription 
factor [10], inhibiting the activation of STAT1 is unlikely to be efficacious in the treatment of 
enthesitis. Our data demonstrated that inhibiting STAT1 expression can be achieved by 
inhibiting the JAK-STAT pathway, suggesting this would be an efficacious therapeutic option 
in spondyloarthritis. It was demonstrated in this article that STAT1 expression is JAK-STAT-
dependent and that treatment of A20myelKO mice with tofacitinib (a JAK inhibitor that mainly 
targets JAK1 and JAK3 [11,12]) results in significantly reduced STAT1 expression and 
enthesitis development. Tofacitinib is currently approved for the treatment of rheumatoid 
arthritis and its efficacy has been demonstrated in several clinical trials. [reviewed in [13]] 
Multiple trials are currently ongoing in spondyloarthritis. The efficacy of tofacitinib in 
psoriatic arthritis has been demonstrated in two phase III trials [14,15] and one of these 
trials demonstrated a significant efficacy of tofacitinib on enthesitis [15] while the other 
abstract did not show data for the effect on enthesitis. [14] The efficacy of tofacitinib in the 
treatment of axial spondyloarthritis has been studied in a phase II trial and demonstrated 
efficacy.[16] However, no data were available on the effect of tofacitinib on enthesitis in this 
clinical trial.  
 
Interestingly, enthesitis development can be triggered by distinct cell types. In the A20myelKO 
model, enthesitis clearly originates from myeloid cells, since myeloid cell-specific A20-
deletion leads to the spontaneous development of enthesitis. However, enthesitis can also 
originate from enthesis resident T cells and this process involves STAT3.[26] The fact that 
JAK-STAT signaling is implied in the pathogenesis of enthesitis in both experimental models 
strengthens the rationale that JAK inhibition would be a potential therapy in 
spondyloarthritis. In our experiments, we used tofacitinib, which mainly targets JAK1 and 
JAK3. Therefore, it is of interest to study the effect of JAK inhibitors with distinct specificities 
for the janus family kinases. Interestingly, recent data show that A20 can modulate IFN-β 
levels and IFN-β is known to signal through the JAK-STAT pathway using a combination of 
JAK1 and TYK2. [17,18] These observations suggest that blocking JAK-STAT signaling with a 
JAK1 specific JAK inhibitor could be as efficacious as blocking the pathway with tofacitinib. 
Moreover, it would be interesting to investigate whether blocking both JAK1 and TYK2 would 
result in a more pronounced effect compared to JAK1 and JAK3 inhibition. Further studies 
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investigating the role of the distinct JAK inhibitors would greatly contribute to our 
knowledge of the pathogenesis of SpA. Moreover, our data were obtained in a TNF-α 
independent mouse model, suggesting that modulation of the JAK-STAT pathway could be a 
therapeutic option in TNF-α blocker refractory patients.   
 
In chapter 4 PHD1 was identified as an important regulator of myeloid cell function in the 
pathogenesis of arthritis. It was demonstrated that hypoxia protects against arthritis 
development in a collagen antibody-induced arthritis (CAIA) model. During hypoxia, the 
activity of all three PHD proteins is inhibited. [19] There are compounds available that inhibit 
all three PHD proteins, but it stands to logic that the benefit-risk balance of a general PHD 
inhibitor would be less appropriate than that of a compound that specifically inhibits the 
PHD protein involved in the pathogenesis of rheumatoid arthritis. The main adverse effects 
here would be expected through PHD2 inhibition. [20] Therefore, we studied the role of the 
individual PHD proteins by inducing a CAIA model in mice with a germline deletion for the 
specific PHDs.  
 
It was demonstrated that PHD1 has an important role in arthritis development, while no 
difference was found in clinical arthritis between PHD2-/+ or PHD3-/- mice and littermate 
controls. Specific germline deletion of PHD1 in mice results in reprogramming of the basal 
glucose metabolism and enhanced hypoxia tolerance in skeletal muscle and liver, without 
angiogenesis and erythrocytosis.[20–22] In PHD1-/- mice, the metabolism shifts from an 
aerobic to a more anaerobic production of ATP. Moreover, these mice are shown to have 
less oxidative stress.[21,22] Further investigation to determine the effect of selective PHD1 
inhibition is necessary to evaluate whether the benefit-risk balance of PHD1 blocking 
therapies would be appropriate in RA patients.  
 
PHD proteins are well-known for their role in HIF-α degradation, but it has recently been 
shown that these enzymes also exert HIF-α independent functions. [19,23,24] PHD1 is 
known to function as a negative regulator of NF-κB in unstimulated conditions. However, it 
was demonstrated that although PHD1-/- BMDMs exhibit increased basal NF-κB activation, 
they show a less potent NF-κB-dependent response after LPS stimulation. [25] Moreover, it 
was demonstrated that PHD1-/- BMDMs were skewed towards an anti-inflammatory M2 
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phenotype. [25] Given the important role of PHD1 in the NF-κB signaling, it is likely that the 
role of PHD1 in arthritis development is NF-κB dependent. Moreover, NF-κB signaling in 
hypoxia was demonstrated to be HIF1α-independent. [26]  This could explain why on one 
hand PHD1 deletion protects against arthritis development, while on the other hand PHD1 
deletion leads to higher HIF-α concentrations and HIF-α is considered a pathogenic factor in 
rheumatoid arthritis. [reviewed in [27]] Our data suggest that the effect of PHD1 deletion on 
NF-κB signaling overrules the pathogenic effect of HIF-α.  
 
Because myeloid cells are considered critical effector cells in the CAIA model, we assessed 
inflammation in myeloid cell-specific PHD1KO mice after induction of a CAIA model. 
Interestingly, these mice developed less arthritis and inflammation-induced bone loss 
compared to wildtype mice indicating that PHD1 in myeloid cells plays an important role in 
the pathogenesis of arthritis. However, whether PHD1 deletion in other cell types also 






Although our work contributed to the knowledge concerning the pathogenesis of enthesitis 
development, it also provoked some additional questions.  Our data demonstrated that A20 
inhibits STAT1 expression, leading to a STAT1 dependent enthesitis. However, the precise 
underlying mechanism of this interaction remains unknown. It was demonstrated in vascular 
cells that A20 negatively modulates INF-β levels and this was suggested to regulate the 
STAT1 expression. Furthermore, it was shown that IFN-β levels were modulated by 
phosphorylated TANK-binding kinase-1 (TBK1) and A20 deficiency led to higher levels of 
phosphorylated TBK1. [17] Interestingly, while it was suggested that this process is NF-κB 
independent in vascular cells [17], the STAT1 expression  appears to be NF-κB dependent in 
astrocytes. [28] It would be therefore interesting to investigate the link between A20 and 
STAT1 expression in more detail.  
 
The efficacy of tofacitinib, a JAK inhibitor who mainly targets JAK1 and JAK3 [11,12], was 
demonstrated in the treatment of enthesitis in a preclinical arthritis model. Moreover, 
tofacitinib has demonstrated a significant effect on enthesitis in psoriatic arthritis patients in 
a phase III trial. [15] However, the effect on enthesitis of JAK inhibitors with a specificity for 
other JAK combinations or for specific JAKs is currently unknown. Further investigation of 
these JAK inhibitors in preclinical models and clinical trials will give us more information on 
the effect of distinct JAK inhibitors in spondyloarthritis and putative differentiating effects 
that may rely on specific JAK members as opposed to others.   
 
It was shown that specific deletion of PHD1 in myeloid cells protects against arthritis 
development. However, whether PHD1 deletion in other cell types also has a protective 
effect on arthritis remains to be determined. Given the important role of T cells in the 
pathogenesis of arthritis, assessment of arthritis development in mice with a T cell-specific 
deletion of PHD1 would be very interesting.  Moreover, since fibroblast play a key role in the 
pathogenesis of arthritis, investigating the role of PHD1 in stromal cells would also provide 
important information on the pathogenesis of rheumatoid arthritis.  In addition, while our 
data point to an indispensable role of PHD1 in modulating arthritis, an additional role for 
PHD2 cannot be ruled out. Because germline deletion of PHD2 results in lethality, we utilized 
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PHD2 hemizygous mice that had similar arthritis severity versus controls. Future studies 
using conditional and cell specific deletion of PHD2 are needed to formally exclude an in vivo 
role for PHD2. 
 
More detailed study of the molecular mechanisms underlying the protective effect of PHD1 
deletion on arthritis development is necessary. We are planning on performing in vitro 
experiments on BMDMs from germline PHD1-/- and PHD1+/+ mice, in which we will assess 
the inflammatory and metabolic responses to both inflammation and hypoxia. The BMDMs 
will be stimulated with several cytokines and antibodies and their reaction to these stimuli 
will be assessed both in normoxic and hypoxic conditions. Moreover, we are planning to 
study the metabolic profile of these cells in the conditions listed above. These experiments 
will enable us to obtain a better insight in the mechanism underlying the role of PHD1 in 
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As discussed in chapter 1, both spondyloarthritis (SpA) and rheumatoid arthritis (RA) are 
prevalent rheumatic disorders that can have a severe impact on the health-related quality of 
life. Although both diseases mainly affect the musculo-skeletal system, there are also 
important differences. While, for example, arthritis in RA starts as an auto-immune synovitis, 
the origin of arthritis in spondyloarthritis is pinpointed to local factors in tissues prone to the 
disease, like entheses. The synovio-entheseal complex is discussed in detail in this chapter, 
since it plays an important role in the pathogenesis of enthesitis, a hallmark of 
spondyloarthritis. A20 (tumor necrosis factor-α induced protein 3) is known to be an 
important negative regulator of NF-κB signaling. Like NF-κB signaling, JAK-STAT signaling has 
an important role in immune responses. Both A20 and the JAK-STAT pathway are discussed 
in the introduction of this thesis.  
All eukaryotic cells fundamentally require oxygen for homeostasis and development. 
Surprisingly, much remains unknown about the role of oxygen supply in inflammation. In the 
introduction an overview of the available information on the link between hypoxia and 
inflammation and on 3 known oxygen sensors: prolyl hydroxylase domain (PHD) proteins 
PHD1, PHD2 and PHD3 is given. Recently, substantial progress has been made both in our 
understanding of the molecular mechanisms underlying the pathophysiology of SpA and RA 
and in therapeutic options in both diseases. 
 
In chapter 2 it was stated that despite the recent progress in the treatment of RA and SpA, 
there still are considerable gaps, two of these being enthesitis and treatment options in TNF-
α blocker refractory patients. Therefore, this PhD project focused on investigating the JAK-
STAT pathway in a TNF-α independent mouse model and on investigating factors that can 
contribute to chronicity of arthritis. The first objective of this PhD project was to investigate 
the pathogenesis of enthesitis. The second objective was to characterize the role of oxygen 




In chapter 3 it was demonstrated that A20 functions as an important regulator of myeloid 
cell biology in the pathogenesis of enthesitis in mice that have a myeloid cell-specific 
deletion of A20 (A20myelKO mice). A20 deletion in myeloid cells leads to an increased 
expression of STAT1 and this results in the spontaneous development of enthesitis. The 
enthesitis is shown to be STAT1-dependent and the STAT1 expression in this mouse model is 
JAK-STAT dependent. Remarkably, a direct link between A20 and STAT1 expression could be 
unraveled. Overall, this article identifies several potential therapeutic targets in the 
treatment of enthesitis.  
 
PHD1 is identified as an important regulator of myeloid cell function in the pathogenesis of 
arthritis in chapter 4. It was shown that hypoxia protects against arthritis development in a 
collagen antibody-induced arthritis (CAIA) model. Since hypoxia is known to inhibit the 
activity of PHD proteins, their contribution to arthritis development was investigated. It was 
demonstrated that loss of Phd1, but not Phd2 or Phd3, provides protection from arthritis 
development. Moreover, Phd1 deletion also protects against inflammation-induced bone 
loss. Myeloid cells are considered critical effector cells upon passive transfer of arthritogenic 
antibodies in the CAIA model; the role of PHD1 was therefore assessed, specifically in 
myeloid cells during arthritis development. Interestingly, mice with a myeloid cell-specific 





Zoals besproken wordt in hoofdstuk 1 zijn spondyloartritis (SpA) en reumatoïde artritis (RA) 
prevalente reumatische aandoeningen die een belangrijke impact op de levenskwaliteit 
kunnen hebben. Hoewel beide aandoeningen voornamelijk het musculoskeletaal stelsel 
aantasten, zijn er ook belangrijke verschillen. Terwijl artritis bij RA bijvoorbeeld ontstaat als 
een auto-immune synovitis, ligt de oorsprong van artritis bij SpA eerder in lokale factoren in 
weefsel dat vatbaar is voor deze aandoening, zoals de entesis. Het synovio-enthesiaal 
complex wordt in dit hoofdstuk in detail besproken, aangezien het een belangrijke rol speelt 
in de pathogenese van entesitis, een belangrijk kenmerk van spondyloartritis. A20 (tumor 
necrosis factor-α induced proteïne 3) is een gekende negatieve regulator van NF-κB 
signalisatie. Net als NF-κB signalisatie heeft ook JAK-STAT een belangrijke rol in de 
reactiviteit van het immuunsysteem. Zowel A20 als de JAK-STAT pathway worden besproken 
in de inleiding van deze thesis. 
Alle eukaryote cellen hebben zuurstof nodig voor hun homeostase en ontwikkeling. 
Verrassend genoeg is er tot op heden nog weinig gekend over de rol van zuurstof en hypoxie 
bij ontstekingen. In de inleiding geven we een overzicht van de beschikbare informatie in 
verband met de interactie tussen hypoxie en ontsteking en drie gekende zuurstofsensoren: 
prolyl hydroxylase domain (PHD) eiwitten PHD1, PHD2 en PHD3. Onlangs werd een 
substantiële vooruitgang geboekt in onze kennis van de moleculaire mechanismen die aan 
de basis liggen van de pathofysiologie van SpA en RA en in onze therapeutische opties voor 
beide ziekten. 
 
In hoofdstuk 2 wordt er gesteld dat, ondanks de recente ontwikkelingen op het gebied van 
behandelingen voor RA en SpA, er toch nog belangrijke verbeteringen mogelijk een nodig 
zijn: onder andere op het vlak van entesitis en de behandelingsmogelijkheden in TNF-α 
blocker refractoraire patiënten. Daarom werd tijdens dit doctoraat de nadruk gelegd op het 
onderzoeken van de JAK-STAT pathway in een TNF-α onafhankelijk muismodel en op het 
onderzoeken van factoren die kunnen bijdragen tot de chroniciteit van artritis. Het eerste 
doel van dit doctoraatsproject is het onderzoeken van de pathogenese van entesitis. Het 
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tweede doel in dit project was het karakteriseren van de rol van zuurstofsensoren in de 
pathogenese van artritis. 
 
In hoofdstuk 3 wordt aangetoond dat A20 een belangrijke regulator is van myeloïde cel 
biologie in de pathogenese van entesitis bij muizen die een myeloïde cel-specifieke deletie 
van A20 hebben (A20myelKO muizen). Het ontbreken van A20 in myeloïde cellen leidt tot een 
verhoogde expressie van STAT1 en dit resulteert op zijn beurt in de spontane ontwikkeling 
van entesitis. In dit hoofdstuk wordt aangetoond dat deze entesitis STAT1-afhankelijk is en 
dat STAT1 expressie in het muismodel JAK-STAT-afhankelijk is. Interessant hierbij is dat er 
een direct verband tussen A20 en STAT1 expressie aangetoond kon worden. Samengevat 
identificeert dit artikel verscheidene potentiële therapeutische targets in de behandeling van 
entesitis. 
 
PHD1 werd in hoofdstuk 4 als belangrijke regulator van de myeloïde cel functie in de 
pathogenese van artritis geïdentificeerd. Er wordt hier aangetoond dat hypoxie beschermt 
tegen   artritis ontwikkeling in een collageen antilichaam geïnduceerd artritis (CAIA) model. 
Omdat hypoxie de werking van PHD eiwitten verhindert, wordt de individuele bijdrage van 
de PHD isotypes bestudeerd in de ontwikkeling van artritis. Er wordt aangetoond dat een 
deletie van Phd1, maar niet van Phd2 of Phd3, bescherming biedt tegen artritis ontwikkeling. 
Bovendien biedt een tekort aan PHD1 ook bescherming tegen inflammatie-geïnduceerd 
botverlies. Myeloïde cellen worden algemeen aanzien als essentiële effector cellen bij de 
passieve transfer van artritogene antilichamen in het CAIA-model. Daarom wordt de rol van 
PHD1 onderzocht in myeloïde cellen tijdens de ontwikkeling van artritis. Muizen met een 
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